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Abstract 
Colistin is one of the key antibiotics to treat infections caused by multi-drug resistant (MDR) 
Gram-negative bacteria. However; in 2015, plasmid mediated colistin resistance, designated 
mcr-1, was first reported in China. MCR-1 was unusually found in Escherichia coli and 
conferred only low levels of resistance to colistin. Soon mcr-1 was found worldwide and 
caused great concern in public health. 
A small number of studies have shown that acquisition of mcr-1 plasmid is associated with no 
or only a slightly decrease in bacterial fitness. In order to assess the capacity to develop high 
colistin resistance in mcr-1 harbouring E. coli and its effect on bacterial fitness and virulence, 
seven wild-type E. coli strains (PN16, PN21, PN23, PN24, PN25, PN42, PN43) from 
Phitsanulok, Thailand were selected and challenged with increased concentration of colistin for 
14 days. All isolates showed an increase in colistin resistance (4- to 64- fold increase in colistin 
MIC up to 256mg/L), and subsequently, designated high level colistin resistant mutants 
(HLCRMs). In all seven HLCRMs, two showed 11- and 3- fold increase in mcr-1 expression 
(PN21 [showed 11-fold] and PN25). No increase in mcr-1 copy number or mutations in the 
immediate genetic context of mcr-1 was detected in all HLCRMs. Interestingly, in PN25 and 
PN42 HLCRMs, amino acid mutations in PmrA and PmrB were identified, respectively.  
Those HLCRMs were associated with significant either fitness burden or reduction in virulence, 
or both. In-vitro fitness was measured by growth rate. Compared with wild-type isolates, 
HLCRMs showed slower growth in colistin-free medium (p <0.01). Competition assays 
showed relative fitness compared HLCRMs with parental strains which ranged for 0.4-0.7 
(p=**) (except for PN16 [relative fitness 0.9]).  
A Galleria pathogenicity model was used to measure the virulence of wild-type strains and 
mutants. In every case, the death rate of Galleria for HLCRMs was lower than that for wild-type 
strains. Significant difference in bacterial mortality were identified in PN16, PN21, PN23 
(p=**/***).  
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Due to its high expression of mcr-1 [11-fold] cellular morphology by transmission electron 
microscopy (TEM) was undertaken on PN21 and its HLCRM to further understand how 
MCR-1 has an effect on bacterial cell outer-membrane. However, no obvious difference on 
outer-membrane between PN21 and mutant was identified.  
The study shows that HLCRMs from wild-type strains are associated with significant fitness 
burden and decrease in virulence. These data will contribute to our understanding of mcr-1 and 
it’s impact on bacterial fitness, and the emergence and management of colistin resistance.  
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1.1 Overview of global antibiotic resistance 
1.1.1 History of antibiotics and resistance 
The discovery of the first two key antibiotics- Prontosil (the first sulphonamide), which 
decreased the mortality of injured soldiers by 50% during the World War I and World War II 
(Domagk, 1965; Gaynes, 2017), and Penicillin, which saved about 12-15 percent of soldiers’ 
lives in the 1940’s (Rao, 2016; Gaynes, 2017) - are recognised as one of the greatest discoveries 
in medicine. The distribution of these drugs not only saved people’s lives but started a new era 
of antibiotics, and laid the foundation of modern pre and post surgical management (Aminov, 
2010; Gaynes, 2017). During the pre-antibiotic era, most people could not live long enough to 
develop cancer, heart disease or other lifestyle diseases and died prematurely, in part, because 
of epidemics, infections by injuries/childbirth etc (Office for National Statistics[GB], 2017). 
This changed dramatically after antibiotics were introduced into public healthcare systems 
(Armstrong, Conn, & Pinner, 1999; World Health Organization, 2018). The previous deadly 
illness such as Pneumonia and Tuberculosis could be treated efficiently, if not completely. 
Mortality from surgical infections and childbirth were also dramatically reduced and common 
injuries would no longer take away people’s life (McKenna, 2015). According to Armstrong et 
al., in the United States, mortality due to infectious diseases declined 92.4% in the 20
th
 century, 
especially from 1938 to 1952. The infectious disease mortality showed a rapid decrease by 8.2% 
per year, with 287 deaths per 100,000 in 1937 to 75 deaths per 100,000 in 1952, respectively 
(Armstrong et al., 1999). Whilst vaccines targeted to specific pathogens, have no doubt 
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contributed to the lowering of mortality, the general use of antibiotics was dominant factor in 
these statistics (World Health Organization, available at 
www.who.int/publications/10-year-review/vaccines/en/ ). 
Concurrently, bacteria were challenged and had to rapidly adapt to these environmental 
changes – as they have they had done for millions of years (McKenna, 2015). Bacteria create, 
share and spread resistance to antibiotics, and the intemperate use of antibiotics in agriculture 
and human medicine has been shown to accelerate this process (McKenna, 2015). Penicillin 
was distributed in 1943, and widespread penicillin resistance appeared by 1945. Imipenem was 
clinically introduced in 1985 and mobile resistance was first witnessed in 1991(Centers for 
Disease Control and Prevention, 2013a; Watanabe, Iyobe, Inoue, & Mitsuhashi, 1991). 
Daptomycin, one of the most recent antibiotics, was introduced in 2003, and resistance 
appeared just one year later in 2004 (Centers for Disease Control and Prevention, 2013a) 
(Figure 1.1). The pharmaceutical companies introduced many new antibiotics to solve, or at 
least negate, the resistance problem, but resistance soon developed and fewer new drugs have 
been introduced (Centers for Disease Control and Prevention, 2013a; Ventola, 2015). 
According to Antibiotic Research UK, only two new antibiotic classes have been clinically 
implemented in the last 40 years, and thus we are facing a dire situation with fewer new, let 
alone novel, antibiotics to fight resistant bacteria (Antibiotic Research UK, retrieved from 
https://www.antibioticresearch.org.uk/about-antibiotic-resistance/ ). Now, after many decades 
of curing infections, the development of multi-drug resistant (MDR) bacteria has become a 
realistic threat to our lives again. According to the Centers for Disease Control and Prevention 
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(CDC), every year more than two million people are infected by antibiotic-resistant bacteria 
resulting in at least 23,000 deaths in the US (Centers for Disease Control and Prevention, 
2013a). In the UK, there are more than 44,000 deaths a year because of sepsis, exceeding the 
number of lung cancer (35,000) and bowel cancer (16,000). Among those, many deaths are due 
to the lack of effective antibiotic treatment (Antibiotic Research UK, retrieved from 
https://www.antibioticresearch.org.uk/about-antibiotic-resistance/ ). The Jim O’Neil report 
commissioned by former UK Prime Minister, David Cameron, predicted that antimicrobial 
resistance (AMR) will account for 10 million deaths in 2050 (O’Neill, 2014). Now we are in a 
lamentable situation: bacteria develop resistance so fast that the creation of new antibiotics 
cannot provide a sustained therapeutic window, and to make it worse, many of the large 
pharmaceutical companies have little interest in antibiotic research because they cannot yield 
any profit (McKenna, 2015; Ventola, 2015). 
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Figure 1.1 Timeline of key events of antibiotic resistance (Centers for Disease Control and 
Prevention, 2013a). 
1.1.2 Cause of antibiotic resistance crisis 
Although AMR occurs naturally, using antibiotics inappropriately in humans and animals is 
accelerating the process (Shallcross & Davies, 2014). At the same time, a lack of new 
antibiotics gives us nowhere to run. The main reasons for the antibiotic resistance crisis today 
are due to overuse of antibiotics and lack of new drugs (Ventola, 2015). 
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1.1.2.1 Overuse of antibiotics in human medicine 
Clearly, the misuse and overuse of antibiotics speed up the evolution of AMR (Ventola, 2015). 
The fact is that antibiotics are heavily overused not only by doctors but outpatients in the 
community (over the counter sales) all over the world and particularly in low-middle income 
countries (LMICs) (Centers for Disease Control and Prevention, 2013a; Van Boeckel et al., 
2014). According to the CDC, in the US nearly 50% of the antibiotics used in humans are not 
needed or are not effective as prescribed (Centers for Disease Control and Prevention, 2013a). 
Studies in the UK demonstrate that almost 50% people visit their GP because of a cough or cold 
hoping to be given antibiotics; and a further study in Wales shows that around 1.6 million 
prescriptions each year are unnecessary (Davies, 2014). Furthermore, the situation in some 
LMICs is worse where antibiotic use is unregulated and over the counter sales rife (Reardon, 
2014). In many LMICs lacking adequate public health care, the market of antibiotics is chaotic 
and completely unregulated - antibiotics can be bought in pharmacies, general stores, and even 
in market stalls without prescription (Nepal & Bhatta, 2018). A study in Yemen, Saudi Arabia, 
and Uzbekistan shows that 48%-78% of the patients purchase antibiotics without prescriptions 
(Belkina et al., 2014). In addition to the uncontrolled use of antibiotics, the quality and potency 
of the drugs are equally worrying (Ayukekbong, Ntemgwa, & Atabe, 2017). In some 
developing countries, antibiotics are produced locally, sometimes illegally and can be 
counterfeit (Ayukekbong et al., 2017; Hart & Kariuki, 1998; Mayor, 2010). According to 
Ozawa et al., in LMICs, nearly seventeen percent of antibiotics are substandard or falsified 
(Ozawa, Evans, Bessias, & et al., 2018). All of this misuse contributes to the emergence of 
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AMR. Moreover, due to frequent international trading and traveling, new types of AMR can be 
spread globally very quickly (Bernasconi et al., 2016; Cavaco & Aarestrup, 2013; D'Aoust, 
1994; Fernando, Collignon, & Bell, 2010). 
1.1.2.2 Irresponsible use of antibiotics in agriculture 
Antibiotics are widely used in livestock to either treat infections, prevent current infections or 
metaphylaxis (treatment of the whole heard) or as a growth promoter (Unno, Kim, Guevarra, & 
Nguyen, 2015). For example, in the pig industry, antibiotics are used routinely to prevent 
disease or to avoid the outbreak of infections because of poor living conditions (Kempf et al., 
2013). In modern farms, normally thousands of animals are kept together indoors with limited 
space and reared solely for the purpose of rapidly gaining weight – greater yield of protein and 
larger profits (Pappas, 2011). Famers also use antibiotics routinely as growth promoters to help 
animals against poor living environment (Davies, 2014; Doyle, 2001). It is estimated by 
European Medicines Agency that two thirds of antibiotics in European countries were used in 
farm animals. In the UK, the rate is about 45%, and 80% in the US (European Centre for 
Disease Prevention and Control, European Food Safety Authority, & European Medicines 
Agency, 2015; Department of Agriculture, Environment and Rural Affairs, 2007; Ventola, 
2015). 
The antibiotics used in farm animals is an important driver of AMR for some major infectious 
bacteria in humans, such as Salmonella and Campylobacter (Davies, 2014). According to the 
WHO, AMR in foodborne bacteria Salmonella and Campylobacter, is clearly the result of 
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antibiotic use in food animals, and has subsequently spread from the food-chain to humans 
(World Health Organization, 2011). This occurs in the following events: antibiotic use in farm 
animals kills susceptible bacteria and either maintains resistant bacteria or the bacteria acquire 
resistance (Centers for Disease Control and Prevention, 2013a). The conditions on farms, 
particularly in resource restricted countries also foster the rapid spread of bacteria from one 
animal to another (Davies, 2014). 
1.1.2.3 Lack of new antibiotics 
The emergence and spread of AMR can be rapid; however, the pace of discovery of new 
antibiotics is glacial by comparison. A decrease in novel and new antibiotics dropped sharply 
after the mid-1990s (Figure 1.2). To make matters worse, most pharmaceutical companies have 
little interest in antibiotic research; 15 of the 18 largest pharmaceutical companies announced 
their intention to leave the antibiotic field due to lack of profit (Bartlett, Gilbert, & Spellberg, 
2013; Ventola, 2015). The CDC and WHO have formally announced that we are running out of 
drugs against Gram-negative infections, including Enterobacteriaceae, Pseudomonas 
aeruginosa, and Acinetobacter (World Health Organization, 2017b).  Although there are still 
22 new antibiotics have either been launched and/or in clinical trials since 2000, they are 
ineffective against MDR Gram-negative infections or lack any novelty i.e. resistance is likely to 
develop very quickly (Butler, Blaskovich, & Cooper, 2013). However, even if novel antibiotics 
are developed, without widespread attitude and behaviour change, antibiotic resistance will 
remain a major threat (Ventola, 2015). 
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Figure 1.2 The number of antibiotic discovered each decade (Wikipedia, retrieved from 
https://en.wikipedia.org/wiki/Timeline_of_antibiotics). 
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1.1.3 Antibiotic-resistant infections  
On global level, MDR in Gram-negative bacteria is extremely serious. According to the WHO, 
there is a serious lack of treatment options for MDR Gram-negative pathogens, including 
Acinetobacter and Enterobacteriaceae (World Health Organization, 2017c). The situation on 
AMR in Gram-positive bacteria, whilst slightly better, is also a cause for concern, among which 
MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant 
Enterococci) are of great concern (Centers for Disease Control and Prevention, 2013a). 
1.1.3.1 MDR Enterobacteriaceae 
Enterobacteriaceae pathogens may cause urinary tract infections (UTI), bloodstream infections 
(BSI), hospital- and healthcare-associated pneumonia, and various intra-abdominal infections 
(Akova, 2016; Malmartel & Ghasarossian, 2016; P. Nordmann, 2014; Paterson, 2006). They 
can spread easily between humans by hand and by contaminated food and water, and can 
readily acquire additional DNA through horizontal gene transfer mediated by plasmids or 
transposons (Patrice Nordmann, Dortet, & Poirel, 2012; Ventola, 2015). Among these, 
Carbapenem-Resistant Enterobacteriaceae (CRE) and extended spectrum β-lactamase 
(ESBL)-producing Enterobacteriaceae are currently of greatest concern (Centers for Disease 
Control and Prevention, 2013a). 
CRE are a group of bacteria that have become resistant to ―all or nearly all‖ antibiotic options 
available, including carbapenems (Ventola, 2015). Carbapenems (imipenem, ertapenem, 
meropenem, and doripenem) are one of the latest developed β-lactams and possess the broadest 
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spectrum of activity (Patrice Nordmann et al., 2012). According to the CDC, in the US, 140,000 
cases of health care associated infections occurred with Enterobacteriaceae, of which 9,300 
were caused by CRE (Centers for Disease Control and Prevention, 2013a). In 2010, an enzyme 
called New Delhi metallo-β-lactamase (NDM) was reported in India and caused great concern 
because it mediated resistance to almost all β-lactams and had quickly spread all around the 
world. (Hammerum et al., 2010; Kumarasamy et al., 2010; D. van Duin & Doi, 2017). Few 
treatment options are available for CRE and these include polymyxins, some aminoglycosides, 
and tigecycline (David Van Duin, Kaye, Neuner, & Bonomo, 2013). 
Enterobacteriaceae producing ESBLs mediates resistance to extended-spectrum penicillins and 
third generation cephalosporins (Cantas, Suer, Guler, & Imir, 2015). An estimate by the CDC 
report that each year, nearly 26,000 (or 19%) healthcare-associated Enterobacteriaceae 
infections were attributed to ESBL-producing Enterobacteriaceae, resulting in 1,700 deaths 
(Centers for Disease Control and Prevention, 2013a). Moreover, mortality of BSI caused by 
ESBL-producing Enterobacteriaceae is approx. 57% higher than that of non ESBL-producing 
strains (Centers for Disease Control and Prevention, 2013a). 
1.1.3.2 MDR Acinetobacter 
Acinetobacter are Gram-negative bacteria that can cause nosocomial pneumonia or 
bloodstream infections, especially among critically ill patients. Many Acinetobacter have 
become resistant to all or nearly all antibiotics and approximately 63% of healthcare-associated 
Acinetobacter infections are caused by MDR Acinetobacter, accounting for 7,000 cases in the 
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US  (Centers for Disease Control and Prevention, 2013a). Among these, 500 cases are not 
responsive to any antibiotics (Centers for Disease Control and Prevention, 2013a). Although 
MDR Acinetobacter rarely cause serious infections in healthy people, it can occur in many 
immunosuppressed patients or in patients with other serious underlying diseases (Dijkshoorn, 
Nemec, & Seifert, 2007; World Health Organization, 2014). Carbapenems and polymyxins are 
often used to treat Acinetobacter infections; however, resistance to carbapenems and 
polymyxins are increasingly reported (Cai, Chai, Wang, Liang, & Bai, 2012; Cheng et al., 2016; 
Dijkshoorn et al., 2007; Gagnaire et al., 2017; Gupta et al., 2016; Ko et al., 2007; López-Rojas 
et al., 2013).  
1.1.3.3 MDR Pseudomonas aeruginosa 
P. aeruginosa is a common cause of nosocomial infections such as hospital-acquired 
pneumonia, complicated urinary tract infections, surgical-site infections, and bloodstream 
infections (Berube, Rangel, & Hauser, 2016). Approximately 8% of all hospital-associated 
infections (accounting for 51,000 cases) reported to CDC are caused by P. aeruginosa, among 
which 13% cases are caused by MDR P. aeruginosa (Centers for Disease Control and 
Prevention, 2013a). Each year, approximately 400 deaths in the US are attributable to infections 
by MDR P. aeruginosa (Centers for Disease Control and Prevention, 2013a). Some MDR P. 
aeruginosa strains are resistant to nearly all β-lactams, aminoglycosides, and fluoroquinolones. 
In such cases, colistin associated with adjunctive therapy (such as a β-lactam or rifampicin) is a 
potential treatment option (Chatterjee & Agrawal, 2016; Obritsch, Fish, MacLaren, & Jung, 
2005; Riethmuller et al., 2016). 
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1.2 Colistin  
The rapid rise of MDR in Gram-negative bacteria has given colistin a renaissance after falling 
out of favour for more than 15-20 years (Biswas, Brunel, Dubus, Reynaud-Gaubert, & Rolain, 
2012). As an old antibiotic, colistin was first introduced into clinical use in Japan, Europe and 
the US in the 1950s, but was then withdrawn due to moderate/severe adverse (toxic) effects 
(Biswas et al., 2012; M. E. Falagas & Kasiakou, 2005; Schwarz & Johnson, 2016). In the 1990s, 
as lack of treatment options for MDR Gram-negative bacteria became a serious issue, colistin 
was introduced back into clinical use and listed as a last-resort antibiotic by WHO (M. E. 
Falagas & Kasiakou, 2005; World Health Organization, 2014). 
1.2.1 Chemical Structure 
Colistin (Polymyxin E) is a member of polymyxin family, a group of cationic polypeptide 
antibiotics, which contains five different derivatives (Polymyxin A, B, C, D and E) (Landman, 
Georgescu, Martin, & Quale, 2008). Polymyxin B and E (colistin) are available in clinical 
practice to treat infections by MDR Gram-negative bacteria (Schwarz & Johnson, 2016). The 
main difference between polymyxin B and E is that polymyxin B contains phenylalanine in 
position 6 while colistin contains D-leucine (Nation, Velkov, & Li, 2014). The major forms of 
polymyxins used worldwide are colistimethate sodium  (CMS) (48.6%) and colistin sulfate
（14.1%, or both forms of colistin (1.4%), while polymyxin B is rarely used (1.4%). Other 
forms are unknown in the study (Wertheim et al., 2013).  
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Colistin was developed from Paenibacillus polymyxa subsp. Colistinus. Its tripeptide side chain 
is connected to the fatty acid residue, which is identified as 6-methyl-octan-oic acid (colistin A) 
or 6-methyl-eptanoic acid (colistin B) (Falagas, Polymyxins, sourced from 
http://www.antimicrobe.org/d05.asp). 
 
Figure 1.3 Chemical structure of colistin.  
(Wikipedia, retrieved from https://en.wikipedia.org/wiki/Colistin.) 
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1.2.2 Spectrum 
Most Gram-negative bacteria are susceptible to polymyxins, including A. baumannii, 
P .aeruginosa, and nearly all Enterobacteriaceae. However, Pseudomonas mallei, Burkholderia 
cepacia, Edwardsiella spp., Brucella spp. and the Proteus-group of Enterobacteriaceae are all 
naturally resistant to polymyxins. Furthermore, Gram-positive bacteria, fungi, and parasites are 
unaffected by polymyxins (Falagas, Polymyxins, sourced from 
http://www.antimicrobe.org/d05.asp ).  
The clinical and Laboratory Standards Institute (CLSI) and the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) provide breakpoints for colistin susceptibility 
for Enterobacteriaceae, P. aeruginosa and A. baumannii (Table 1.1). In general, an isolate with 
Minimum Inhibitory Concentration (MIC) ≤ 2mg/L is deemed as susceptible. 
Table 1.1 Breakpoints of colistin susceptibility (MIC, mg/L) according to guidelines in 
United States (CLSI) and Europe (EUCAST) S, sensitive; I, intermediate; R, resistant.
（M100S Performance Standards for Antimicrobial Susceptibility Testing 2018）(European 
committee on antimicrobial susceptibility testing 2018). 
Species 
CLSI  EUCAST 
S I R  S R 
Enterobacteriaceae ≤2 4 ≥8  <2 ≥2 
P. aeruginosa ≤2 4 ≥8  <2 ≥2 
A. baumannii ≤2 4 ≥8  <2 ≥2 
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1.2.3 Application of Colistin 
Colistin is used in clinical practice for both adults and children as a treatment option for 
infections caused by MDR Pseudomonas, MDR A. baumannii and CRE (Tamma et al., 2013). 
However, the emergence of colistin resistance is rapidly rising and deeply concerning (Tamma 
et al., 2013). 
In veterinary medicine, colistin is widely used to prevent infections in livestock caused by 
Escherichia coli, such as diarrhoea, septicaemia and colibacillosis (Kempf et al., 2013). High 
colistin use has been observed in epidemiological studies in Europe (Kempf et al., 2013). In 
countries such as China, Thailand and Vietnam, high doses of colistin have also used as feed 
additives for growth promotion in both large and small farms (Nguyen et al., 2016; Walsh & 
Wu, 2016; Wongsuvan, Wuthiekanun, Hinjoy, Day, & Limmathurotsakul, 2018). China has 
recently banned colistin as a growth promoter in April 2017 because of the discovery of the 
mobile colistin resistance gene, mcr-1 (Liu et al., 2016; Walsh & Wu, 2016).  
1.2.4 Mechanism of action 
Colistin and Polymyxin B have a similar mechanism of activation. The structure of polymyxin 
contains a cyclic decapeptide bound to a fatty acid chain. The L-Dab molecules in polymyxin 
are positively charged, while the lipopolysaccharides (LPS) of Gram-negative bacteria are 
negatively charged (Velkov, Roberts, Nation, Thompson, & Li, 2013). Colistin binds to LPS in 
the bacterial cell outer-membrane, displace divalent cations such as Mg
2+
 and Ca
2+
 (which are 
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associated with stabilizing LPS molecules), and leads to increased permeability of cell 
outer-membrane, resulting in leakage of cell contents and cell death (Velkov et al., 2013).  
1.2.5 Colistin Resistance 
The main mechanism of colistin resistance is modification of lipid A with 
phosphoethanolamine （PEA） or 4-amino-4-arabinose （L-Ara4N）, resulting in lowering the 
affinity with polymyxins, or in rare cases the loss of LPS (Hinchliffe et al., 2017).  In addition 
to these, the use of efflux pumps may also aid colistin resistance (Abiola O Olaitan, Morand, & 
Rolain, 2014). The following examples are key mechanisms of colistin resistance: 
1.2.5.1 PmrA/B, PhoP/Q two-component system (TCS)  
PmrA/B and PhoP/Q TCSs are the regulators of LPS modifications in many bacterial species. 
(Chen & Groisman, 2013) The activation of PmrA/B TCS leads to expression of 
PmrA-dependent genes resulting in resistance to polymyxins (Chen & Groisman, 2013), while 
the activation of PhoP/PhoQ TCS leads to polymyxin resistance by indirectly activating 
PmrA/PmrB TCS via PmrD (Abiola O Olaitan et al., 2014). Mutations in these two systems can 
cause constitutive over-expression, resulting in the subsequent activation of the arnBCADTEF 
and pmrCAB operons and the synthesis and transfer of lipid A by L-Ara4N and 
lipopolysaccharides (PEA), respectively (Chen & Groisman, 2013). Modification of L-Ara4N 
and PEA decrease the net negative charge of LPS and reduce its avidity for colistin (Abiola O 
Olaitan et al., 2014). In addition, inactivation of the mgrB gene (which encodes a 
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negative-feedback regulator of the PhoQ/PhoP signalling system) leads to up-activation of 
PhoQ/PhoP, and subsequently results in modification of LPS mediated resistance to colistin 
(Abiola O Olaitan et al., 2014; Poirel et al., 2014).  
 
 
 
Figure 1.4 Lipopolysaccharide-modification involved in polymyxin resistance in 
Gram-negative bacteria (Chen & Groisman, 2013).  
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1.2.5.2 lpxA, lpxC, and lpxD 
In A. baumannii , mutations in three lipid A biosynthesis genes- lpxA, lpxC, and lpxD lead to the 
complete loss of LPS resulting in very high resistance against colistin (MIC >128 mg/L) 
(Moffatt et al., 2010). LPS is an important component at outer-membrane in Gram-negative 
bacteria, creating a permeability barrier to prevent large molecules from freely entering the cell 
(G. Zhang, Meredith, & Kahne, 2013). The loss of LPS leads to loss of a binding target for 
colistin, resulting in high resistance (Moffatt et al., 2010). 
1.2.5.3 Efflux pump 
Efflux pump system plays an important role in AMR and has been found to be linked with the 
mediation of resistance to cationic antimicrobial peptides such as polymyxins (Falagas, 
Polymyxins, sourced from http://www.antimicrobe.org/d05.asp ). For example, the Emr pump 
system in A. baumannii has been proven to be associated with the adaptation to osmotic stress 
and colistin resistance (Lin, Lin, & Lan, 2017); the MexAB-OprM efflux pump in P. 
aeruginosa can provide resistance to colistin (Pamp, Gjermansen, Johansen, & Tolker‐Nielsen, 
2008; Schweizer, 2003); and the AcrAB efflux pump can cause colistin resistance in Klebsiella 
pneumoniae and E. coli (Padilla et al., 2010; Warner & Levy, 2010).  
1.2.5.4 mcr-mediated colistin resistance 
In 2015, a transferable resistance gene to colistin called mcr-1 was first reported in China, 
which was located on a conjugative plasmid in E. coli ( Liu et al., 2016). mcr-1 represents a 
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―new‖ machinery for colistin resistance where the modification of Gram-negative bacterial 
lipid A is catalyzed by the MCR-1 enzyme, showing a decreased affinity to polymyxin 
(Hinchliffe et al., 2017). Now, mcr-1 has been reported worldwide and is a cause of great 
concern (Schwarz & Johnson, 2016). Following the detection of mcr-1, more plasmid-mediated 
colistin resistant genes- mcr-2, mcr-3, mcr-4 and mcr-5, have been reported (Borowiak et al., 
2017; Carattoli et al., 2017; Xavier et al., 2016; Yin et al., 2017). The continuing identification 
of novel mcr genes indicates a much wider global dissemination of colistin resistance 
determinants in Enterobacteriaceae (Kluytmans, 2017). 
1.2.6 Adverse Events 
As an old antibiotic, colistin was first introduced into the clinic in the 1950s, but then was 
withdrawn due to its adverse side effects, including nephrotoxicity and neurotoxicity (Matthew 
E Falagas & Kasiakou, 2006). However, the antibiotic resistance crisis together with a lack of 
new or novel drugs has given colistin a renascence and it is now widely used to treat serious 
Gram-negative infections (Das, Sengupta, Goel, & Bhattacharya, 2017). 
1.2.6.1 Nephrotoxicity 
Polymyxins can cause nephrotoxicity, and colistin shows less cytotoxic compared to 
Polymyxin B (Falagas, Polymyxins, retrieved from http://www.antimicrobe.org/d05.asp ). The 
mechanism of colistin nephrotoxicity is due to an increase in tubular epithelial cell membrane 
permeability, resulting in increased influx of cations, anions and water mediating cell swelling 
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and lysis (Javan, Shokouhi, & Sahraei, 2015). The nephrotoxicity depends on the concentration 
and length of exposure to polymyxins (Falagas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ). Co-administration with other nephrotoxic drugs, 
patient-related factors (such as age, sex, other kidney diseases and severity of patient illness) 
are also related to colistin nephrotoxicity (Javan et al., 2015).  
Clinical studies show that the frequency of nephrotoxicity of polymyxins varies from as low as 
0% to as high as 55% (Falagas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ). In an early study (1965) by Tallgren et al., 36% patients 
with acute or chronic renal disease showed an increase in plasma creatinine levels 
(TALLGREN, LIEWENDAHL, & KUHLBÄCK, 1965). After the re-introduction of colistin 
into clinical treatment for MDR Gram-negative infections, the data did not support the high 
incidence of polymyxin nephrotoxicity previously reported (Matthew E Falagas & Kasiakou, 
2006). Two studies in intensive care units (ICUs) showed that 14.3% (Markou et al., 2003) and 
18.6% (Michalopoulos, Tsiodras, Rellos, Mentzelopoulos, & Falagas, 2005) of patients had 
demonstrable deterioration in renal function during colistin therapy. To reduce the potential 
damage of colistin to the kidney, it is important to stop polymyxin treatment as soon as primary 
signs of renal dysfunction are recognised (Falagas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ). 
1.2.6.2 Neurotoxicity 
Compared with nephrotoxicity, the incidence of colistin related neurotoxicity is substantially 
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less (Wadia & Tran, 2014). The reported neurological toxicity of colistin is associated with 
dizziness, generalized muscle weakness, facial and peripheral paresthesia, partial deafness, 
visual disturbances, vertigo, confusion, hallucinations, seizures, ataxia, and neuromuscular 
blockade (Falagas, Polymyxins, retrieved from http://www.antimicrobe.org/d05.asp ). Clinical 
studies showed that the most frequently neurological adverse effects were paresthesias, and 
patients with impaired renal function or myasthenia gravis have higher risk of neurological 
adverse effects (Nigam, Kumari, Jain, & Batra, 2015). 
1.2.6.3 Other adverse events 
Other adverse events such as pruritus, dermatoses, drug fever and gastrointestinal disturbances 
may also occur during colistin therapy. Leukopenia and granulocytopenia may also be 
associated with colistin treatment (Falagas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ). Furthermore, people with an allergy to bacitracin are at 
higher risk of hypersensitivity reactions with the use of polymyxins (Falagas, Polymyxins, 
retrieved from http://www.antimicrobe.org/d05.asp ). 
1.2.7 Dosage 
Two forms of colistin are clinically available - colistin sulfate and colistimethate sodium (CMS) 
(Falagas, Polymyxins, retrieved from http://www.antimicrobe.org/d05.asp ). Colistin sulfate is 
usually administered orally for bowel decontamination or is used as treatment of skin infections 
caused by bacteria. CMS is often used for parenteral therapy and is less toxic with fewer 
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adverse events (Falagas, Polymyxins, retrieved from http://www.antimicrobe.org/d05.asp ).  
The recommended dose of CMS in adult patients is different in countries. Generally, 1mg of 
CMS equals 12,500 IU. In the European countries except for France, CMS is recommended at 
4-6mg/kg or 50,000-70,000 IU/kg daily in 2-3 divided doses (Falagas, Polymyxins, retrieved 
from http://www.antimicrobe.org/d05.asp ). In France, 75,000-150,000 IU/kg CMS is 
recommended daily, divided in 1-3 doses. The maximum dosage one day is no more than 12 
million IU (Theuretzbacher, 2014). In the US, the recommended dose of CMS is 2.5-5 mg/kg in 
2-4 doses daily. (Falagas and Vardakas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ) For Children, the adult dosing of colistin is 
recommended (Falagas and Vardakas, Polymyxins, retrieved from 
http://www.antimicrobe.org/d05.asp ). However, current data in children is limited and most 
cases are for the treatment of P. aeruginosa in cystic fibrosis patients where dosing schemes are 
empirical. Therefore, the dose for children has not been defined (Falagas and Vardakas, 
Polymyxins, retrieved from http://www.antimicrobe.org/d05.asp ). 
Furthermore, colistin dosage must be reduced for patients with impaired renal function, and for 
obese patients, the dosage should depend on daily weight (Coly-Mycin, 2005). Although 
colistin is listed in the FDA (US Food and Drug Administration) pregnancy category, it should 
be only be used when the potential benefit is greater than risk (Kazy, Puhó, & Czeizel, 2005).  
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1.3 Transferable colistin resistant gene- mcr-1 
1.3.1 Discovery of mcr-1  
In 2015, Liu et al., first reported transferable colistin resistance mediated by a plasmid from 
food animals in China. The colistin resistance gene, mcr-1, was located on an IncI2-type 
plasmid and conferred a colistin MIC at 8 mg/L ( Liu et al., 2016). Successful transfer of mcr-1 
carrying plasmid to E. coli C600 by conjugation indicated the potential spread of colistin 
resistance under natural conditions. This first report showed that mcr-1 carriage in E. coli was 
also found in meat, chickens, pigs and humans (Liu et al., 2016). The report was significant not 
only because it described a new mechanism of colistin resistance, but indicated that MCR-1 
positive E. coli (MCRPEC) are widespread (Schwarz & Johnson, 2016).  
1.3.2 Global Spread of mcr-1 
Following this first report, incidences of mcr-1 were soon reported worldwide: Asia (China, 
Japan, South Korea, Malaysia, Thailand, Cambodia, Laos and Vietnam), Europe (Denmark, 
France, Germany, UK, Poland, Spain, Portugal, Switzerland, Italy, Belgium and The 
Netherlands), Africa (Egypt, Algeria, Nigeria and South Africa), South and North America 
(Argentina, Canada and the USA) (M. S. Arcilla et al., 2016; Coetzee et al., 2016; Falgenhauer, 
Waezsada, Yao, et al., 2016; Figueiredo et al., 2016; Hasman et al., 2015; Hu, Liu, Lin, Gao, & 
Zhu, 2016; Izdebski et al., 2016; Khalifa et al., 2016; Kluytmans–van den Bergh et al., 2016; 
Kusumoto et al., 2016; Lim et al., 2016; Liu et al., 2016; Malhotra-Kumar, Xavier, Das, 
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Lammens, Butaye, et al., 2016; Malhotra-Kumar, Xavier, Das, Lammens, Hoang, et al., 2016; 
McGann et al., 2016; Mulvey et al., 2016; A. O. Olaitan, Chabou, Okdah, Morand, & Rolain, 
2016; A. Quesada et al., 2016; Rapoport et al., 2016; Schwarz & Johnson, 2016; Stoesser, 
Mathers, Moore, Day, & Crook, 2016; Webb et al., 2016; Zurfuh et al., 2016). The bacterial 
host of mcr-1 are various, including E. coli, Salmonella spp., K. pneumoniae, Enterobacter 
aerogenes, Enterobacter cloacae (Doumith et al., 2016; Du, Chen, Tang, & Kreiswirth, 2016; 
Liu et al., 2016; Webb et al., 2016; Zeng, Doi, Patil, Huang, & Tian, 2016), from a wide range 
of sources, including animals (livestock, pet animals and several wild-birds), food (meat and 
vegetables), water, patients and healthy people (Maris S Arcilla et al., 2016; Liakopoulos, 
Mevius, Olsen, & Bonnedahl, 2016; Liu et al., 2016; Mendes et al., 2018; Schwarz & Johnson, 
2016; J. Wang et al., 2017; X. F. Zhang et al., 2016; Zurfuh et al., 2016). 
Liu et al., analysed 2649 E. coli isolates (523 samples of raw meat, 804 of animals and 1322 of 
inpatients) collected during 2011-2014 in China, which showed MCRPEC rates of 15%, 21% 
and 1%, respectively (Liu et al., 2016). Suzuki et al., reported that five of 671 isolates collected 
from patients, animals and environment from Japan during 2000-2014 were MCRPEC. 
Interestingly, all of the five mcr-1 positive isolates were from animal samples (Suzuki, Ohnishi, 
Kawanishi, Akiba, & Kuroda, 2016). However, Kusumoto et al., found that 45% of E. coli 
isolates collected from diseased swine in Japan during 1991–2014 showed resistance to colistin, 
among which 29% were MCRPEC (Kusumoto et al., 2016). A report from France during 
2007-2014 showed that prevalence of MCRPEC was 5.9% in turkeys, 1.8% in broilers and 0.5% 
in pigs (Perrin-Guyomard et al., 2016). Colistin resistance in Spain was detected in 0.5% E.coli 
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in clinical isolates from 2012–2015, among which 15 of 50 available colistin resistant isolates 
were MCRPEC (Prim et al., 2016). A report from the UK identified 15 mcr-1-positive isolates 
(13 Salmonella enterica and 3 E. coli isolates from patients, 2 S. enterica isolates from poultry 
meat) from ~24 ,000 Enterobacteriaceae (including S. enterica, E. coli, Klebsiella spp., 
Enterobacter spp., Campylobacter spp. and Shigella spp.) isolated between 2012 and 2015 
(Doumith et al., 2016). These global reports support the concern that mcr-1 has been spread 
worldwide. Additionally, with air travel and trade exchanges between countries, no country can 
possibly avoid the acquisition of mcr-mediated colistin resistance (Rhouma, Beaudry, & 
Letellier, 2016). 
Even though the emergence of mcr-1 was first reported in 2015, it was also detected in isolates 
dating back to 1980s (1987) from China and predates the discovery of all mobile 
carbapenemase genes (Shen, Wang, Shen, Shen, & Wu, 2016). Thus, transferable colistin 
resistance existed in the gut flora of food animals for more than 25 years without being detected 
(Schwarz & Johnson, 2016; Shen et al., 2016). The outbreak of colistin resistance is, in part, 
due to the increasing use of colistin in agriculture and aquaculture, particularly since 2007-8 
(Rhouma, Beaudry, & Letellier, 2016). According to Shen et al., the presence of colistin 
resistance and mcr-1 positive rates were at a minimal level which increased sharply during 2009 
to 2014 in China. During this period, the annual use of colistin increased from 2470 to 2875 
metric tons in food animals and therefore is likely to have contributed to the rapid spread of 
mcr-1 in China (Shen et al., 2016). 
41 
 
1.3.3 Analysis of molecular characterization 
1.3.3.1 mcr-1 carrying plasmid 
mcr-1 is normally located on stable plasmids, while rarely on the chromosome (Matamoros et 
al., 2017). Matamoros et al., analysed the population structure of E. coli and the mobile genetic 
elements carrying the mcr-1 gene that had been reported worldwide. Up to 2017, 13 plasmid 
incompatibility types had been reported carrying mcr-1 (Refer to Figure 1.5).  Among these, 
90.4% of the identified plasmids belonged to IncX4 (35.2%), IncI2 (34.7%), IncHI2 (20.5%) 
plasmid types. Interestingly, 65.8% of the IncI2 plasmids carrying mcr-1 were reported from 
Asia, while the major plasmid type carrying mcr-1 in Europe was IncI2 plasmids (73.3%) 
(Matamoros et al., 2017). The distribution of these 3 plasmid types from animal (p = 0.24), 
human (p = 0.88) and environmental sources (p = 0.38) was not significantly different 
(Matamoros et al., 2017). 
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Figure 1.5 Global phylogenetic analysis of plasmids carrying the mcr-1 gene (Matamoros 
et al., 2017)  
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Interestingly, the co-existence of IncX4 with other replicons such as IncHI2 and IncI2 were 
detected in mcr-1 positive bacteria (J. Sun et al., 2017). A study by Sun et al., displayed the 
existence of two copies of mcr-1 located separately on two inc types from the same E. coli 
strain. Furthermore, they also found multiple copies of mcr-1 located on both plasmid and 
chromosome in the same strain (J. Sun et al., 2017). 
1.3.3.2 Population structure 
Multi-locus sequence typing (MLST) is an accurate procedure for characterising isolates of 
many bacterial species. According to Matamoros et al., among 410 Enterobacteriaceae in 215 
studies, MCRPEC showed a high overall diversity of in its population structure. The 410 strains 
represents 112 sequence types, among which ST10 was the most prevalent (12.8%) 
(Matamoros et al., 2017). Reported ST types of mcr-1 harbouring isolates from different origins 
worldwide were shown in Figure 1.6. 
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Figure 1.6 ST types of mcr-1 isolates from different origins (Y. Wang et al., 2017). 
1.3.3.3 Mobile genetic elements 
In mcr-1 carrying isolates, an ISApl1 transposon element is often found upstream of mcr-1 on 
IncHI2 or IncI2 plasmid (Matamoros et al., 2017). In the study by Matamoros et al., 77.8% 
mcr-1 on IncHI2 plasmids is flanked by ISApl1 upstream, while only 37.9% of IncI2 plasmids. 
No Insertion element has been reported upstream of mcr-1 in IncX4 plasmids (Matamoros et al., 
2017).  
ISApl1 encodes a putative transposase belongs to IS30 family (J. Liu et al., 2008) and is a key 
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component in the mobilization of mcr-1 (Snesrud et al., 2016). Its movement is independent of 
mcr-1 (Snesrud et al., 2017). Studies have shown that under certain condition when ISApl1 is 
highly active, its movement may be detrimental to the host cell (Snesrud et al., 2017).  
1.3.3.4 Multiple resistant genes on mcr-1 harbouring plasmid 
In the first report of mcr-1, the mcr-1 carrying plasmid did not carry other resistance genes (Liu 
et al., 2016). However, in later reports, mcr-1 plasmids often harbour other resistance genes 
such as ESBL and carbapenemase genes (McGann et al., 2016; R. Wang et al., 2018; H. Zhang, 
Seward, Wu, Ye, & Feng, 2016). These plasmids not only support the co-transfer of resistance 
genes, but also the existence of mcr-1 under selective antibiotic pressure even without colistin 
(Schwarz & Johnson, 2016). 
1.3.4 Mechanism of MCR-1  
The mechanism of colistin resistance by MCR-1 is due to the modification of LPS on bacterial 
cell outer-membrane (Liu et al., 2016). Briefly, mcr-1 encodes a transferase enzyme belonging 
to the PEA transferase enzyme family which catalyzes the addition of PEA to lipid A moiety of 
LPS through which reduces the negative charge resulting in reduction of colistin avidity, and 
therefore colistin resistance (Hinchliffe et al., 2017).  
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Figure 1.7 PEA transfer reaction catalysed by MCR-1 (Hinchliffe et al., 2017). 
MCR-1 has 41% and 40% identity to the PEA transferases LptA and EptC (Liu et al., 2016), 
and the fold of the MCR-1 catalytic domain is similar to that of the LptA and EptC transferases 
(Stojanoski et al., 2016). LptA is usually being found in Neisseria and specifically transfers 
PEA to only lipid A phosphoryl groups which then confers colistin resistance, while EptC (in 
Campylobacter jejuni) displays a broader substrate tolerance (Liu et al., 2016). Phylogenetic 
analyses showed that MCR-1 is highly homologous to the PEA lipid A transferase in 
Paenibacili, a producer of polymyxins (Gao et al., 2016). 
The recent released MCR-1 crystal structure infers that the catalytic domain of 
membrane-bound MCR-1 is a zinc metallo-protein with three disulphide bonds (see Figure 1.8) 
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(Hinchliffe et al., 2017). Zinc, disulphide bonds and conserved active site residues (including 
zinc ligands, the acceptor Tr285 and additional positions adjacent to the metal centre) are all 
vital to MCR-1 function in E. coli (Hinchliffe et al., 2017).  
 
 
Figure 1.8 Crystal Structure of MCR-1 catalytic domain. A.B. Overall fold of MCR-1 
catalytic domain. The crystal structures reveal an overall α-β-α fold and contain 3 
intramolecular disulphide bonds (labelled). Active site is boxed and formed in C and D; C.D. 
Active site of MCR-1 enzyme (Hinchliffe et al., 2017). 
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1.3.5 Continuous discovery of new transferable colistin-resistant genes 
Following the discovery of mcr-1 in 2015, other plasmid carrying genes encoding colistin 
resistance were reported; namely, mcr-2, mcr-3 etc (Xavier et al., 2016; Yin et al., 2017). The 
latest mobile colistin resistance gene reported is mcr-8 (Wang et al., 2018). 
The mcr-2 gene is a 1,617 bp long phosphoethanolamine transferase gene harboured on an 
IncX4 plasmid and shows 76.75% nucleotide identity to mcr-1 (Xavier et al., 2016). mcr-2 
showshigher prevalence (20%) in colistin-resistant E. coli in Belgium than mcr-1 (13%) 
(Xavier et al., 2016). mcr-3 shows 45.0% and 47.0% nucleotide sequence identity to mcr-1 and 
mcr-2, respectively (Yin et al., 2017). Interestingly, MCR-3 shows 75.6%-94.8% identity to 
phosphoethanolamine transferases found in Aeromonas species (Yin et al., 2017). Moreover, a 
transposon element, named TnAs2, which has only been characterized in Aeromonas 
salmonicida, is identified upstream of mcr-3. The ∆TnAs2-mcr-3 element found from genome 
sequencing and reported from many countries suggests the likelihood of mcr-3 global 
dissemination (Yin et al., 2017). 
Now, mcr-4 and mcr-5 genes have been identified indicating a much wider global 
dissemination of colistin resistance determinants in Enterobacteriaceae (Borowiak et al., 2017; 
Carattoli et al., 2017).  
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1.4 Fitness cost of antimicrobial resistance 
Antibiotic resistance occurs under the selective pressure of antibiotics (Xiong, Sun, Ding, Wang, 
& Zeng, 2015). The continuing existence of antibiotics helps AMR bacteria survive and 
successfully compete against susceptible phenotype (Tech, 2017). Today, the extensive 
resistance to antibiotics and lack of pipeline drugs is a cause of great concern; therefore, the 
biological cost (such as growth and survival rates inside/outside a host, transmission rates and 
pathogenesis protential) seems to be a strand of potential hope of making it possible to reverse 
antibiotic resistance (D. I. Andersson, 2003; Hernando-Amado, Sanz-Garcia, Blanco, & 
Martinez, 2017). 
The hypothesis that antibiotic resistance may bring a biological cost to bacterial hosts comes 
from the analysis of antibiotic resistant mechanisms. Bacteria acquire resistance by two 
different genetic events: recurrent mutation (including recombination) and horizontal genes 
transfer (Sommer, Munck, Toft-Kehler, & Andersson, 2017). The impact of antibiotic 
resistance varies according to different events. In mutation-driven resistance, mutations usually 
happen in genes encoding antibiotic targets or transporter systems (e.g. porins), which are 
intrinsically linked to cellular physiology (Hernando-Amado et al., 2017). Therefore, their 
mutations indicate a less proficient function and a lowering of competitiveness compared to 
sensitive wild-type isolates (Björkman & Andersson, 2000; Melnyk, Wong, & Kassen, 2015). 
In the case where resistance is acquired via horizontal transfer, a physiological burden is 
expected as a consequence of the resources required for replication, transcription and 
translation of mobile genetic elements (Hernando-Amado et al., 2017). Concurrently, the 
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synthesized products may interfere with cellular physiology (Hernando-Amado et al., 2017; 
Lenski, 1998). 
Therefore, the analysis of biological cost of antibiotic resistance is important if we hope to 
predict resistance development or evaluate the possibility of reducing antibiotic resistance, as 
real-time studies both in clinical or laboratory show the effect of antibiotic resistance on 
bacterial fitness and how mutations can influence the trajectory of adaptive evolution under 
selective pressure (D. I. Andersson & Hughes, 2011; Sommer et al., 2017). Several theoretical 
and experimental studies have demonstrated that the cost of antibiotic resistance is a key factor 
to determine the rate or maintenance of resistance under certain antibiotic pressures or without 
the presence of antibiotics (Melnyk et al., 2015). For example, Levin and colleagues used a 
mathematical model to understand the relationship between antibiotic treatment and the 
frequency of resistant genotypes (Levin et al., 1997). According to that model, as long as hosts 
are treated with an antibiotic, a residual population of resistant bacteria would be found. 
Moreover, a decrease in the frequency of AMR bacteria would be seen under a reduction of 
antibiotic treatment (Levin et al., 1997). Thus it seems possible that healthier sensitive 
genotypes could outcompete their MDR counterparts and therefore, displace resistant 
populations in the absence of antibiotic selection over time (dan i Andersson & hughes, 2010). 
In other words, temporarily ceasing antibiotic use can help eliminate resistant bacteria by 
allowing sensitive genotypes to out-compete the resistant population (Melnyk et al., 2015).  
Fitness deficit is variable depending on the mutation, the organism, and the model used to 
determine the cost (Pope, McHugh, & Gillespie, 2010). The biological cost of resistance can be 
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measured in essentially three ways. Firstly, fitness can be evaluated by the growth parameters. 
The simplest way to determine fitness is to grow both resistant and susceptible isolates in vitro 
and to measure the density of each culture over time (Melnyk et al., 2015). Secondly, 
competition assays between susceptible ―parents‖ and resistant mutants (daughter cells) can be 
created to evaluate the physiological vigour of the isolates. Fitness is shown as the ratio 
between susceptible and resistant strains after serial passaging the mixture under antibiotic-free 
conditions (Melnyk et al., 2015). Thirdly, in vivo assays are useful to measure fitness cost and 
are more relevant to clinical conditions. Several animal models are recommended, such as mice, 
chickens, Galleria mellonella, Caenorhabditis elegans, and cell cultures. Animal models can 
also be applied on competition experiments between two culture by measure the modification 
of ratio after several days (Pope et al., 2010). 
Fitness cost of colistin resistance has been reported in some species, especially in A. baumannii 
and K.pneumoniae (Beceiro et al., 2014; Choi & Ko, 2015; Da Silva & Domingues, 2017). Two 
mechanisms have been described in Acinetobacters, one is mentioned PmrA/B mutation 
resulting in modification of LPS, the other is complete loss of LPS by lpxA, lpxC, or lpxD 
mutation (Adams et al., 2009; Moffatt et al., 2010; W. Zhang et al., 2017). Beceiro and 
colleagues compared fitness cost and impact on virulence of both mechanisms and showed that 
complete loss of LPS gave very high colistin resistance (MIC >128 mg/L), while PmrA/B 
mutations showed MIC increases from 2-8 mg/L to 16-64 mg/L. Both mechanisms caused a 
significant decrease in bacterial fitness; however, no significant decrease in virulence was 
detected in PmrA/B mutants (Beceiro et al., 2014). Also, López-Rojas et al., published studies 
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about fitness burden and decrease in virulence by pmrA and pmrB mutations, respectively 
(López-Rojas et al., 2011; López-Rojas et al., 2013). Recently, Mu et al., compared serum 
resistance from both LPS-loss and LPS-modified mutants and showed that both LPS-loss and 
LPS-modified mutants decreased resistance to serum (Mu et al., 2016). However, in some other 
studies, colistin resistance by PmrA/B mutations were not associated with reduction of fitness 
or virulence. According to Durante-Mangoni, colistin resistance caused by a P233S substitution 
in the PmrB sensor kinase did not associate with reduction in bacterial fitness or virulence 
(Durante-Mangoni et al., 2015). These results might suggest that the cost in fitness or virulence 
caused by PmrA/B mutations was variable due to location, type, and number of mutations 
(Beceiro et al., 2014). 
In K. pneumoniae, loss of fitness and virulence was normally associated with colistin resistance. 
In addition to the PmrA/PmrB TCS, mutations in the PhoP/PhoQ two-component regulatory 
system can also lead to colistin resistance (Chen & Groisman, 2013). Additionally, mutations in 
mgrB are related to colistin resistance, as its product MgrB conveys feedback between 
PmrA/PmrB and PhoP/PhoQ TCSs (Poirel et al., 2014; Wright et al., 2015). Cannatelli et al., 
compared the fitness of two KPC-producing K. pneumoniae isolated obtained from same 
patient after low dosage of colistin treatment. Acquisition of colistin resistance after colistin 
treatment was associated with pmrB mutations but showed no reduction in fitness (Cannatelli et 
al., 2014). Furthermore, they also reported no significant biological cost or reduction in 
virulence (Arena et al., 2016; Cannatelli, Santos-Lopez, Giani, Gonzalez-Zorn, & Rossolini, 
2015). Finally, Kidd et al., found enhanced virulence in a mgrB mutant, which mediated a 
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128-fold increase in colistin MIC but showed no change in bacterial growth or biofilm 
formation (Kidd et al., 2016). As K. pneumoniae can cause a wide range of infections, the lack 
of fitness cost of colistin resistance may lead to higher dissemination of resistance and 
undermine the treatment of K. pneumoniae infections (Paczosa & Mecsas, 2016) .  
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1.5 Aims of the Project 
Resistance mutations are expected to have an effect on fitness because their targets have 
important functions on bacterial physiology (Melnyk et al., 2015). Colistin resistance is always 
due to the modification or loss of LPS of bacterial cell outer-membrane, resulting in reduction 
of fitness and virulence (Abiola O Olaitan et al., 2014). Previous studies have shown that 
colistin resistance caused by chromosomal mutation can be associated with reduction of 
bacterial fitness in A. baumannii, P. aeruginosa, K. pneumoniae and S. enterica (Choi & Ko, 
2015; Da Silva & Domingues, 2017; Lee, Park, Chung, Na, & Ko, 2016; S. Sun, Negrea, Rhen, 
& Andersson, 2009). However, this biological cost is variable among different mutations, some 
of these point mutations are proved to have less fitness cost or even no fitness cost (Beceiro et 
al., 2014). 
Hitherto, little has been known about fitness and virulence in mcr-1 harbouring isolates. Zhang 
et al., showed that no reduction in fitness was found between mcr-1 positive transconjugates 
and E .coli J53 (Y. Zhang et al., 2017). This may indicate that acquisition of mcr-1 carrying 
plasmid is cost free (Hernando-Amado et al., 2017).  As the production of mcr-1 normally 
gives relatively low resistance in E. coli (4-16 mg/L colistin MIC) (Liu et al., 2016) compared 
to chromosomally mediated mechanisms, it is of interest to explore the effects of increasing 
colistin resistance in mcr-1 positive isolates. Furthermore, as colistin resistance disseminates 
with the prevalence of mcr-1 (Shen et al., 2016), it is important to determine whether there is 
fitness cost with mcr-1 and consequently, provide a limitation to colistin resistance. 
55 
 
Thus, the aims of this study are to acquire mcr-1 positive high-level colistin resistant mutants, 
and to measure the change in bacterial fitness and virulence and to assess their stability. Whole 
genome sequencing (WGS) on the isogenic sets analysis will also be undertaken.   
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Chapter 2: Methods and Materials 
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2.1 strains used in this study 
Table 2.1 Strains used in this study 
No. Identification Date of isolation Location Source 
PN16 E.coli 27 October 2013 Phitsanulok, Thailand chicken meat 
PN21 E.coli 12 February 2014 Phitsanulok, Thailand chicken faeces 
PN23 E.coli 22 February 2014 Phitsanulok, Thailand duck faeces 
PN24 E.coli 22 February 2014 Phitsanulok, Thailand duck faeces 
PN25 E.coli 22 February 2014 Phitsanulok, Thailand duck faeces 
PN42 E.coli 15 November 2013 Phitsanulok, Thailand faeces from healthy 
human 
PN43 E.coli 15 November 2013 Phitsanulok, Thailand faeces from healthy 
human 
2.2 Antibiotics, chemicals and regents 
Colistin sulfate used in this study was obtained from Alfa Aesar, USA. 
2.3 Growth medium 
2.3.1 Urinary tract infection (UTI) agar (Sigma-Aldrich, USA) 
Ingredients per litre 
Peptic digest of animal tissue 18.0 g 
Casein enzymic hydrolysate 4.0 g 
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Beef extract 4.0 g 
Chromogenic mixture 12.44 g  
Agar15.0 g 
Final pH (at 25 ℃) 7.2+/- 0.3 
Suspend 55.4 g medium in 1 litre distilled water. Sterilize at 121℃ for 15minutes.  
Table 2.2 Cultural characteristics of UTI agar 
Organisms (ATCC) Growth Colour of colony 
E. coli (25922) +++ Pink-red 
Proteus mirabilis (10975) +++ Light brown 
K. pneumonia (13883) +++ Blue to purple (mucoid) 
P. aeruginosa (27853) +++ colourless 
S. aureus (25923) +++ Golden yellow 
Enterococcus faecalis (29212) +++ Blue (small) 
2.3.2 LB agar (Fisher Scientific, UK) 
Ingredients per litre 
Tryptone 10.0 g 
Yeastn extract 5.0 g 
Sodium Chloride 10.0 g 
Agar 5.0 g 
Suspend 40 g in 1 litre of purified water. 
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2.3.3 LB broth (Fisher Scientific, UK) 
Ingredients per litre 
Tryptone 10.0 g 
Yeastn extract 5.0 g 
Sodium Chloride 5.0 g 
Suspend 20 g powder in 1 litre of purified water. 
2.3.4 BBL™ Mueller Hinton (MH) II broth (Cation-Adjusted) (BD Biosciences, USA) 
Ingredients per litre 
Beef extract 3.0 g 
Acid hydrolysate of casein 17.5 g  
Starch 1.5 g 
Final pH 7.3+/- 0.1 
Suspend 22 g of the powder in 1 litre of purified water. Autoclave at 116-121 ℃ for 10 
minutes.  
2.3.5 Mueller Hinton (MH) II agar (BD Biosciences, USA) 
Ingredients per litre 
Beef extract 2.0 g 
Acid hydrolysate of casein 17.5 g 
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Starch 1.5 g 
Agar 17.0 g 
Final pH 7.3+/- 0.1 
Suspend 38 g of the powder in 1 litre of purified water. Autoclave at 121 ℃ for 15 
minutes.  
2.3.6 M9 medium (Sigma-Aldrich, UK) 
Ingredients per litre 
Ammonium chloride 1 g 
Disodium hydrogen phosphate 6 g 
Potassium dihydrogen phosphate 3 g 
Sodium chloride 0.5 g 
Final pH 7.4+/- 0.2 
2.4 Generation of HLCRMs 
The optical density (OD) of overnight culture was adjusted to 0.08- 1.0 at 600 nm, and 
bacterial sample was further diluted 20 X before being grown in MH broth with 0, 0.25, 
0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 mg/L colistin overnight at 37℃. After that the last well 
with bacterial growth and first well without growth were mixed together and incubated 
for 6 hours at 37℃. The OD600nm of mixture was adjusted to 0.08-1.0 and diluted for 20 
more times before being grown with colistin. The same steps were repeated for 14 days 
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to get HLCRMs.  
2.5 Minimum inhibitory concentration (MIC)  
1) Preparation of antibiotic stock solution and dilution range  
Colistin was diluted serially with MH broth in 96-well plate with a final concentration 
from 128 mg/L to 0.25 mg/L (100 µL each well), the first row was left as a colistin zero 
(Table 2.3). 
2) Preparation of bacterial inoculum  
OD of overnight culture was adjusted to 0.08-0.1 at 600nm, before further diluted to 1 in 
10 with MH broth. ATCC25922 was used as quality control. 
3) Sample (100 µL each well) and antibiotic were mixed and grown for 16-20 hours at 
37℃.  
4) After incubation， the concentration of colistin for the first row without bacterial 
growth was identified as MIC. 
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Table 2.3 MIC template in 96-well plate for colistin 
 Colistin(mg/L) 
 0 0.25 0.5 1 2 4 8 16 32 64 128  
Sample A 
           Clean 
LB 
Sample A 
           Clean 
LB 
Sample B 
           LB& 
colistin 
Sample B 
           LB& 
colistin 
Sample C 
           - 
Sample C 
           - 
Sample D 
           - 
Sample D 
           - 
  
2.6 Polymerase chain reaction (PCR) 
PCR was carried out using illustra puReTaq Ready-To-Go PCR Beads (GE Healthcare Life 
Sciences, UK) in a final volume of 20 μL, also containing 1 µL DNA template, 1 µL loading 
dye, 0.5 µL forward primer(10-20 µmol), and 0.5 µL reverse primer(10-20 µmol) (Table 
2.4). Primers were purchased from Urofins Genomics, UK. Molecular water 
(ThermoFisher Scientific, UK) was used to make up the final volume of 20 µL. 
mcr-1 PCR was performed for 1 cycle at 94 ℃ for 5 minutes, then 30 cycles of sequential 
incubation for 30 seconds at 95 ℃, 1 minute at 52 ℃ and 1 minute at 72 ℃. To finish the 
reaction, an extension cycle at 72 ℃ for 10 minutes was taken. 
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Table 2.4 Sequences of primers and probes used in this study 
Primer/Probe Sequencing(5’-3’) Size (bp) Reference 
mcr-1 F GCTACTGATCACCACGCTGT 953 (Yang et 
al., 2017) mcr-1 R TGGCAGCGACAAAGTCATCT  
mcr-1-qF TGGCGTTCAGCAGTCATTAT  
mcr-1-qR AGCTTACCCACCGAGTAGAT  
mcr-1 probe ROX-AGTTTCTTTCGCGTGCATAAGCCG- BHQ1  
rpoB-qF TCCTTTCTATCCAGCTTGACTCGT 200 
rpoB-qR CGCAGTTTAACGCGCAGCGG 
rpoB probe HEX-ACGTCAGCTACCGCCTTGGCGAACCGGTGT
BHQ1 
 
16S-qF CATTGA CGTTACCCGCAGAA 100 
16S-qR CGCTTTACGCCCAGTAATTCC 
16S probe FAM-CGTGCCAGCAGCCGCGGTA-TAMRA  
 
2.7 Agarose gel electrophoresis 
After the PCR reaction, the reaction mixture was loaded onto an agarose gel to size and 
fractionate the DNA fragment. Hi-Res Standard Agarose (Cambridge Reagents Ltd, UK) 
was used at 1.5% in 1 X TBE buffer. Ethidium bromide was added to a final concentration 
of 0.1 µg/mL in the gel. A 1kB plus DNA ladder (Lambda PFG Ladder, New England 
Biolabs, UK) was used to ascertain the size of DNA fragments. Electrophoesis was done 
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at 300V for 30 minutes. DNA patterns were visualised and recorded by G:BOX Chemi XX6 
gel imaging system (Synoptics Ltd, UK).  
2.8 Stability of HLCRMs  
Stability of HLCRMs was detected by serial passaging in colistin-free medium. Overnight 
culture of HLCRMs was diluted by 1:500 into LB broth without colistin and was 
incubated for 18h at 37℃ at 220rpm. Same process was repeated for 14 days. To further 
measure the proportion of colistin resistant population, Overnight culture was diluted 
serially and was inoculated on antibiotic-free agar plates as well as on agar plates with 
0.5 X MIC to colistin of respective HLCRMs. After 18-22h incubation at 37℃, the 
colony-form units (CFU)/ml of colistin-resistant cells were counted. 
2.9 Preparation for genomic DNA 
Genomic DNA was extracted using QIAcube system (Qiagen, Germany), using QIAGEN 
spin-column kits (Qiagen, Germany), according to manufacturers’ protocol. 
2.10 Real time quantitative polymerase chain reaction (RT-qPCR) 
2.10.1 Expression of mcr-1 
Expression of mcr-1 for both wild-type isolates and HLCRMs were detected by a 
two-step qRT-PCR using primers mcr-1-qF, mcr-1-qR (Table 2.4) and mcr-1 probe with 
Precision 2x qPCR Mastermix (PrimerDesign, UK).  
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1) Reverse Transcription: Total RNA was isolated using RNeasy Plus kit (Qiagen, 
Germany) with on column DNase digestion, followed by cDNA synthesis using 
QuantiTect Reverse Transcription kit (Qiagen, Germany).  
2) Real-Time PCR: PCR amplification was done in a 20 µL reaction volume for the 
96-well plates in the absence of reverse transcriptase, using a StepOnePlus System 
(Thermofisher Scientific, UK). rpoB expression level was used as positive control using 
primers rpoB-qF, rpoB-qR and rpoB probe (Table 2.4). Relative expression results were 
calculated by the comparative CT analysis method using average CT value. 
2.10.2 mcr-1 copy number  
mcr-1 copy numbers per cell was determined by qPCR amplification. PCR amplification 
was done in a 20 µl reaction volume for the 96-well plates, using a StepOnePlus System 
(Thermofisher Scientific, UK). 0.1 ng of total genomic DNA was used as template with 
primers (mcr-1 qF/qR, or 16S qF/qR) and probe (mcr-1 or 16S probe) (Table 2.4). 
Standard curve for mcr-1 was obtained using as template serial dilutions of 
mcr-1-carrying plasmid DNA extracted from pSU18-mcr-1 strain (single copy of 
mcr-1per cell) (4.3 ng of DNA corresponding to 106 copies, calculated through the 
website: http://cels.uri.edu/gsc/cndna.html)(Yang et al., 2017). And that for 16S was 
obtained using as template serial dilutions of mcr-1-carring plasmid DNA extracted from 
E. coli TOP10 (Invitrogen, UK) total genomic DNA (5 ng corresponding to 106 cells). The 
absolute copy number of mcr-1 in the E. coli total DNA samples was determined from the 
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corresponding standard curves, using the CT values.  
2.11 S1 pulsed-field gel electrophoresis (S1-PFGE) 
S1-PFGE was performed according to the standard operating procedure and DNA 
restriction was under Toleman’s protocol (Centers for Disease Control and Prevention, 
2013b; Toleman, 2018). 
2.11.1 Buffers and reagents 
1) TE buffer (10 mM Tris:1 mM EDTA, pH 8.0) 
10 ml of 1 M Tris, pH 8.0  
2 ml of 0.5 M EDTA, pH 8.0  
To a total volume of 1000 ml with sterile ultrapure clinical laboratory reagent water 
(CLRW) 
2) Cell suspension buffer (100 mM Tris:100 mM EDTA, pH 8.0) 
100 ml of 1 M Tris, pH 8.0  
200 ml of 0.5 M EDTA, pH 8.0 
To a total volume of 1000 ml with sterile ultrapure water (CLRW) 
3) Cell lysis buffer (50 mM Tris:50 mM EDTA, pH 8.0 + 1% Sarcosyl)  
50 ml of 1 M Tris, pH 8.0  
100 ml of 0.5 M EDTA, pH 8.0 
100 ml of 10% Sarcosyl (N-Lauroylsarcosine, Sodium salt)  
To a total volume of 1000 ml with sterile ultrapure water (CLRW) 
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4) 10 X Tris-boric acid/EDTA (TBE) buffer 
Tris base 108.0 g 
Boric acid 55.0 g 
0.5 M EDTA (pH 8.0) 20.0 mL 
To a total volume of 1000 ml with sterile ultrapure water (CLRW) 
5) 1/10 TE buffer (1 mM Tris-HCl, 0.1 mM EDTA, pH 8.0). 
5 mL of 1 X TE is diluted to 50 mL with sterile ultrapure water (CLRW) to produce 1/10 
X TE buffer. 
6) 1 X S1 buffer (30 mM sodium acetate pH 4.6, 1 mM ZnSo4, 5% glycerol). 
10 X S1 buffer is prepared as: 
12.3 g of Sodium acetate 
0.92 g Zinc acetate 
200 mL sterile ultrapure water (CLRW) 
250 mL of glycerol 
Final pH 4.6 
To a final volume of 500 mL with sterile ultrapure water (CLRW) 
5 mL of 10 X S1 buffer is diluted to 50 mL with sterile ultrapure water (CLRW) to 
produce 1 X S1 buffer.  
*10 X S1 buffer needs to be stored at -20℃. 
7) 0.5 X TBE (45 mM Tris-HCl, 45 mM boric acid, 1 mM EDTA). 
100 mL of 10 X TBE is diluted to 2000 mL with sterile ultrapure water (CLRW) to 
produce 0.5 X TBE. 
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2.11.2 Making plugs with SeaKem Gold (SKG) agarose (Lonza, Switzerland) 
Bacterial colonies were inoculated into 2 ml cell suspension buffer (with a final 
concentration of OD 0.8-1.0 at 600nm). 400 µl cell suspensions were mixed with 400 µl 
melted 1% SKG agarose and 20 µl of Proteinase K (20 mg/ml stock), before dispensed 
into clean plug mold.  
2.11.3 Lysis of cells in agarose plugs 
Plugs were transferred into 5 ml cell lysis buffer with 25 µl Proteinase K (20 mg/ml 
stock) and were incubated at 55 °C at 150-175 rpm for 1.5-2 hours.  
2.11.4 Washing of agarose plugs after cell lysis 
After Incubation with cell lysis buffer, plugs were washed with 10-15 ml pre-heated 
sterile ultrapure water (CLRW) for two times, then with 10-15 ml pre-heated sterile TE 
buffer for four times, shaking at 55°C for 10-15 minutes each wash. Plugs could be stored 
in TE buffer at 4 °C.  
2.11.5 Restriction digestion of DNA in agarose plugs 
After washing, plugs were incubated in 300 µL 1/10 TE for 5 minutes at room 
temperature and then pre-restricted by 200 µL S1 buffer for 5 minutes at room 
temperature. Restriction was done by 200 µl S1 enzyme master mix (1 unit of S1 nuclease 
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[Invitrogen, UK]) overnight at 4˚C. After restriction, plugs were treated with 200 µL 0.5 X 
TBE for 5 minutes at room temperature before loading into1% SKG agarose (melted with 
0.5 X TBE). Lambda PFG Ladder (NEB, UK) was used as marker. 
2.11.7 Electrophoresis Condition 
Gel was run on a CHEF-DR III apparatus (Bio-Rad, Hercules, CA, USA) under following 
conditions.  
Initial switch time: 4s 
Final switch time: 45s 
Voltage: 6 V 
Included Angle: 120° 
Run time: 18 hours  
2.12 In gel hybridisation 
After the electrophoresis, the gel was dried and then dealt with direct agarose gel 
probing (Toleman, 2018). 
2.12.1 In gel hybridisation components 
1) Denaturing solution (0.5 M NaOH, 1.5 M NaCl) 
20 g NaOH  
87.66 g NaCl 
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To a total volume of 1000 ml with sterile ultrapure water (CLRW) 
2) Neutralising solution (0.5 M Tris-HCl, PH 7.5, 1.5 M NaCl) 
60.5 g Tris base 
87.6 g NaCl 
Final pH7.5 
To a total volume of 800 ml with sterile ultrapure water (CLRW) 
3) Pre-hybridisation solution:  
(6 X SSC, 0.1%[W/V] ) polyvinylpyrrolidone 
0.1% Ficoll,  
0.5% SDS 
150 mg/L Herring testes DNA 
1 mL full cream milk 
To a total volume of 20 mL with sterile water (CLRW) 
2.12.1 Pre- hybridisation 
Once dried, the gel was re-hydrated in the following steps: 200 mL deionized DNase-free 
water for 5 minutes, 200 mL denaturing solution at room temperature for 45 minutes 
and 200 mL neutralising solution for 45 minutes at room temperature. Then re-hydrated 
gel was moved to a hybridisation tube and incubated with 20 mL pre-hybridisation 
solution at 65 °C for 24 hours. 
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2.12.2 Probe preparation and hybridisation 
mcr-1 probe was prepared by random priming labelling method using purified mcr-1 
positive PCR product (using QIAquick Gel Extraction Kit (Qiagen, Germany)) with 
radio-active 32P dCTP (Stratgene, Amsterdam, Netherlands) as a label, according to 
manufacturers’ instructions. Once labelled, unincorporated 32P dCTP and unlabelled 
nucleotides were removed by a sephadex G50 gravity flow gel filtration column 
(illustraTM NickTM Columns Sephadex G-50 DNA grade, GE Healthcare Life Sciences, 
UK). Labelled probe was boiled for 6 minutes before added into pre-hybridised gel 
overnight at 65 °C. 
2.12.3 Film development 
After hybridisation, gel was washed with 100 mL 2 X SSC, 0.1% SDS for one hour at 65 °C 
before put into film cassette. Detection film used was Lumi-Film Chemiluminescent 
Detection film (Roche, Germany). Films were developed using standard film 
development and fixer solutions. 
2.13 Growth rate  
To test the growth curve, 10 μL overnight culture was added into 10 mL LB broth and 
incubate at 37ºC at 220 rpm for 8 hours. OD value at 492 nm was measured every one hour. 
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2.14 Competition assay by flow cytometry 
Competition assay was tested for seven wild-type strains and seven HLCRMs using flow 
cytometry. Green fluorescent protein (GFP)-labelled DH5-α was used as control. All 
competitions were carried out in M9 medium (Sigma-Aldrich, UK) with six replicates per 
strain/condition. Flow cytometry was performed on an Accuri C6 (BD Biosciences, UK). 
Briefly, overnight culture was diluted by 1:400 for each wild-type strain, HLCRM and 
GFP-labelled DH5-α around 1000 events per 1 μL in M9 broth. Each diluted sample 
strain was mixed with GFP-labelled DH5-α at the ratio of around 50:50 (±10), and 
incubated at 37 ºC at 220 rpm for 6 hours. The starting ratio between wild-type 
strains/HLCRMs and GFP-labelled DH5-α was measured by flow cytometry. After 6 
hours’ incubation, the bacterial mixture was diluted by 1: 400, and the final ratio 
between sample strains and GFP-DH5-α was measured by flow cytometry. Relative 
fitness was calculated between each wild-type strain/HLCRM and GFP-DH5-α by 
formula below. 
Fitness =
log2 (
𝑝1
𝑝0/𝑛dilution
)
log2 [
1 − 𝑝1
(1 − 𝑝0)/𝑛dilution
]
 
p0 stood for the initial proportion of an unlabelled stain, and p1 stood for the final 
proportion of an unlabelled stain after competition. ndilution was the factor that reflected 
the fold difference in cell density at the beginning/end of the competition.  
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The relative fitness of HLCRMs to their parental strains was further calculated by ƒHLCRM/ƒ 
parental for each repeat, and error propagation was used to account for the uncertainty. 
SE = √(
SDHLCRM
ƒ ̅HLCRM
)
2
+ (
SDparental
ƒ ̅parental
)
2
 
2.15 Galleria mellonella pathogenicity model 
Pathogenicity in vivo was examined in a Galleria model. G. mellonella caterpillars (Live 
Foods UK Ltd., http://www.livefood.co.uk) were stored in the dark and were used within 
7 days from shipment. 
1) 10 mL overnight culture was centrifuged at 4000-6000 rpm for 10 minutes and 
bacterial pellet were washed with 5mL sterile normal saline twice. 
2) Washed bacterial pellet were standardised in suspensions with sterile normal saline 
equating to 1x109, 108, 107, 106 and 105 CFU/ml. 
3) 10 healthy G. mellonella larvae with similar size (15-20 mm) and weight 
(approximately 0.2 g) were manually selected for each level of inoculation in triplicate. 
Each group of larvae were placed into a sterile 10 x 10 mm Petri dish. 
4) Selected larvae were injected with 10 μL of suspension into the hemocoel using a 
Hamilton Syringe, through the rear left pro-leg, and were incubated at 37 ºC for 72 
hours.  
5) The amount of died and alive worms was checked every 24 hours. Death was denoted 
when larvae no longer respond to touch and exhibit grey/dark pigmentation. 
6) Data were analysed by Kaplan-Meier survival curves using GraphPad Prism 7.0. 
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2.16 DNA sequencing 
2.16.1 Illumina WGS and bioinformatics analysis 
Whole genome sequencing (WGS) was carried out on the HLCRM isolates using the Illumina 
MiSeq platform (Illumina Inc., CA). Briefly, gDNA was extracted from an overnight culture 
(2 ml) using the QIAcube automated system (Qiagen, Germany), and resulting gDNA were 
quantified using the Qubit 3.0, using the dsDNA high sensitivity assay (Thermos Fisher 
Scientific), with quality ratios of gDNA (A260/280 and 260/230) determined via Nanodrop 
(ThermoFisher Scientific). DNA libraries were prepared for paired-end sequencing (2 x 301 
cycles) using Nextera XT (Illumina). Quality control (QC) of raw sequence reads included 
fastqc (0.11.2), and quality and adaptor trimming were performed using Trim galore (0.4.3). 
For each E. coli isolate, at least 80 X coverage was generated. Reads were assembled in 
contigs using the de novo assembler SPAdes (3.9.0) (.fasta) and were aligned to the original 
fastq reads using BWA aligner (0.7.15). Any assembly mapping errors in the contigs was 
corrected, using Pilon (1.22). Assembly metrics were evaluated using Quast (2.1). MLST loci 
(by MLST 2.0), acquired resistance genes (by ResFinder 3.1, with minimum 90% identity and 
80% coverage), and plasmid replicons (by PlasmidFinder-2.0, using Enterobacteriaceae 
database with minimum 95% identity and 80% query coverage) were retrieved from the 
online databases (CGE platform: https://cge.cbs.dtu.dk/services/).  
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2.16.2 Nanopore sequencing and bioinformatics analysis 
High-molecular weight gDNA was extracted from the HLCRM following a 
chloroform-precipitation method. The total gDNA was quantified following a serial dilution 
using the Qubit 3.0 and the quality was assessed following the metrics as described above. 
Sequencing libraries were prepared using the Rapid Barcoding Kit (SQK-RBK004) following 
manufacturers’ instructions. Following a QC check of the Nanopore flowcell (R9.4) just 
before use, over 1, 200 active pores were detected. The flowcell was primed according to the 
manufactures guidelines, and the library was gently mixed using a pipette tip, and loaded onto 
the Nanopore flowcell (R9.4). WGS was performed for 48 hours using a MinION and 
associated MinKNOW software. Raw fastq sequences were concatenated and the HLCRM 
were de-barcoded using Porechop. Unicycler (Wick, Judd, Gorrie, & Holt, 2017) was used to 
create a hybrid assembly with a combination of MiSeq short reads and MinION (Oxford 
Nanopore) long reads. The resulting hybrid assembly was visualised using Bandage to 
confirm complete genome assembly of the chromosome and plasmids.  
Single nucleotide polymorphisms (SNPs) between wild-type strains and corresponding 
HLCRMs were analysed using Geneious 10.2.6. The circular comparisons among 
mcr-1-related IncX4 and IncI2 plasmid backgrounds were performed using BLAST Ring 
Image Generator (BRIG v0.95).  
2.17 Bacterial morphology by transmission electron microscopy (TEM) 
Briefly, overnight culture was diluted into 50 ml fresh LB media with 2 mg/L colistin. 
After an 8-hour incubation, glutaraldehyde was added to the sample with a final 
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concenreation of 1%. Sample was fixed in 4% low melting point agarose, dehydrated 
through graded propan-2-ol, and infiltrated and embedded through LR white acrylic 
resin (London Resin Company, UK). After embedding, sections of 80 nm thickness were 
cut on an Ultracut E. ultramicrotome with a glass knife and collected on mesh copper 
grids and strained by lead citrate before observation with a Philip CM12 TEM (FEI UK 
Ltd, UK) at 80 kv. Images were captured by a Megaview III digital camera and AnalySIS 
(Soft Imaging System GmbH, Germany). 
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Chapter 3: Results 
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3.1 Identification of mcr-1 positive strains and acquisition of HLCRMs 
3.1.1 Bacteria strains and susceptibility testing. 
The aim of this study is to acquire high colistin resistant mutants (HLCRMs) and to examine the 
fitness cost of mcr-1 to the host bacterium. For this purpose, seven mcr-1 positive wild-type E. 
coli strains from different origins (PN16 from chicken meat, PN21 from chicken faeces, PN23, 
PN24, PN25 from duck faeces and PN42, PN43 from human faeces) from Phitsanulok, 
Thailand were selected for this study.  
3.1.2 Generation of high-level colistin resistant mutants (HLCRMs) 
MICs were performed by broth micro-dilution for each strain and colistin MICs ranged from 4 
to 8 mg/L – all demonstrating low-level resistance to colistin (Liu et al., 2016). This data is 
consistent with previous studies that report colistin MICs with mcr-1 positive E. coli strains 
range from 4-16 mg/L (Liu et al., 2016; Rhouma, Beaudry, Theriault, & Letellier, 2016). To 
produce HLCRMs, wild-type isolates were treated with increasing concentrations of colistin in 
continuous culture for 14 days. A portion of the population was removed each day and colistin 
MICs were determined by broth micro-dilution. E. coli ATCC 25922 was used as a QC strain.  
After 14-days of passaging, all isolates demonstrated an increase in colistin MIC (Table 3.1 and 
Figure 3.1). The highest increase was seen in PN43 with a 64-fold increase in colistin MIC to 
256 mg/L. The colistin MIC against PN23 HLCRM also reached 256 mg/L, followed by PN16, 
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PN21 and PN25 at 128 mg/L. Whilst PN24 and PN42 showed only a 4- and 8-fold increase to 
16 mg/L and 32 mg/L, respectively. Throughout the passaging, the E. coli were stored daily at 
-80 ºC until further required. However, the Day14 mutant for PN16 was too weak to grow from 
-80 ºC, and therefore the Day13 mutant was used as the end-point HLCRM for PN16.  
Table 3.1 MICs of colistin against wild-type strains for 14-day passaging 
 MIC of colistin (mg/L) 
Day PN16 PN21 PN23 PN24 PN25 PN42 PN43 
1 8 4 8 4 8 4 4 
2 8 8 8 4 8 8 4 
3 8 8 8 4 8 8 4 
4 8 8 16 4 8 8 8 
5 16 8 16 4 8 8 8 
6 32 8 32 8 16 16 16 
7 16 16 32 8 16 16 16 
8 16 16 32 8 32 32 16 
9 16 32 128 16 32 32 32 
10 16 32 128 16 32 32 64 
11 16 64 128 16 64 32 128 
12 16 64 128 16 64 32 128 
13 32 64 128 16 64 32 256 
14 128 128 256 16 128 32 256 
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Figure 3.1 Generation of HLCRMs over a passaging period of 14 days. Seven wild-type 
MCRPEC were treated with increasing concentration of colistin for 14 days.  
qRT-PCR was performed for mcr-1 to examine whether the increase in colistin resistance is 
associated with mcr-1 expression. Results indicated that the expression of mcr-1 in 6 mutants 
increased compared to their respective parental strains. HLCRMs of PN21 and PN25 showed 
the highest increase in mcr-1 expression with 11- and 3- fold, respectively. HLCRMs of PN16, 
PN23, PN24 and PN43 displayed a 1.2- to 1.9-fold change compared to their respective parent 
strains. However, the MCR-1 expression level of HLCRM PN42 showed no discernible 
increase in expression but a slight decrease (Figure 3.2 A). 
Furthermore, mcr-1 copy number was also examined in the HLCRMs by qRT-PCR. The copy 
number for wild-type isolates ranged from 1 (chromosomal copy for PN43) to 5.6 (PN23). 
Increase in the mcr-1 copy number was seen in PN16, PN21 and PN25 mutants (Table 3.2 and 
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Figure 3.2 B). 
Table 3.2 mcr-1 copy number per cell comparing Day0 (parent) and Day14 (HLCRM) 
(mcr-1 copies/cell) 
Strain PN16 PN21 PN23 PN24 PN25 PN42 PN43 
Day0 3.1 2.1 5.6 4.3 1.8 3.2 1 
Day14 3.6 3.8 3.5 2.1 3.3 1.5 1 
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Figure 3.2 A. mcr-1 expression represented as fold-change comparing Day14 to Day0. 
Relative changes of mcr-1 expression (Day14 compared to Day0) were calculated using 
∆∆CT analysis method by mean CT value (n=2). 
B. mcr-1 copy number expressed as fold-change comparing Day14 to Day0. Fold changes 
in mcr-1 copy number were obtained by comparing each Day14 and Day0 strains. 
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3.1.3 Stability of HLCRMs 
Stability experiments were undertaken for each HLCRM to examine their ability to maintain 
higher levels of resistance to colistin. This was achieved by passaging in LB broth without 
colistin over a period of 14 days and numerating the HLCRMs (CFU/ml) on Müller-Hinton 
agar plate with 16, 32, 64, 128 mg/L colistin and without colistin. 
Difference in CFU/ml for each day was demonstrated in log phase (Figure 3.3). For three of the 
HLCRMs (PN24, PN25 and PN42) the CFU/ml (overall bacterial population) remained at the 
same level after 14 days passaging without colistin, indicating that their HLCRMs were highly 
stable. The other strains showed a varying decrease in CFU/ml after 14 days, especially for 
PN43 where the CFU/ml dropped gradually but continuously and after ten days, no growth on 
at 128 mg/L colistin could be detected. HLCRMs PN16, PN21 and PN23 also showed 
significant decrease in their HLCRM populations over 14 days, indicating that their respective 
HLCRMs are not particularly stable.  
Colistin MICs were performed on strains isolated during the 14-day passaging without colistin 
The MICs were generally kept consistent with CFU/ml levels except for PN21 and PN43. 
Interestingly, even though the CFU/ml for strains PN21 and PN43 decreased to a very low-level 
after 14 days, their MICs were kept at 128 mg/L and 256 mg/L, respectively (Table 3.3).  
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Figure 3.3 Stability of HLCRMs after 14-day passaging without colistin. CFU/ml was 
grown on media with/without colistin, ratio of CFU/ml with/without colistin was calculated. 
 
Table 3.3 MICs of wild-type strains, high level mutants and stability strains 
MIC of colistin (mg/L) 
 Wild-type HLCRM(Day14) Stability 
         8 32(Day13) 8 
PN21 4 128 128 
PN23 8 256 64 
PN24 4 16 16 
PN25 8 128 64 
PN42 4 32 32 
PN43 4 256 256 
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3.1.4 Location of mcr-1 comparing Day 0 parent isolates and HLCRMS (Day 14) 
To locate the mcr-1 gene, S1-PFGE and southern blot were undertaken and analysed (Figure 
3.4). Results showed that except for PN43, all mcr-1 genes were located on different size of 
plasmids. No obvious plasmid size change was found between original wild-type isolates and 
respective mutants. The mcr-1 gene of PN43 is located on chromosome, which is very unusual 
although has been previously reported  (Falgenhauer, Waezsada, Gwozdzinski, et al., 2016). 
Figure 3.4 S1-PFGE analysis of wild-type isolates and their corresponding Day14 
HLCRMs. In-gel hybridization with 
32
P-labelled mcr-1 gene probe after PFGE of nuclease S1 
digested genomic DNA. 
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3.1.5 Whole genome sequencing (WGS) analysis 
WGS was proposed on each wild-type isolate and HLCRM using Illumina. In addition, five 
HLCRMs (of PN16, PN24, PN25, PN42, PN43) were also sequenced by nanopore long reads 
and were corrected by Miseq short reads.  
The mcr-1 gene from these isolates were located on an Incl2 plasmid (PN16 and PN21) and 
IncX4 plasmid (PN23, PN24, PN25 and PN42), respectively. Unusually, mcr-1 for strain PN43 
was located on the chromosome. In addition to mcr-1, these isolates also harboured other 
resistance genes (see appendix section). The isolates were examined for different sequence 
types (MLSTs) and identified the following MLST groups: ST-2040, ST24*, ST-1121, ST-7986, 
ST-101, ST-744, and ST-410. I also determined the mcr-1 copy number by qPCR and found the 
plasmid number to be ranging from 1 to 5.6 copies per cell.  
In addition to PN43, the mcr-1 harbouring plasmids of the six wild-type E. coli isolates 
belonged to IncI2 and IncX4 plasmid types, with sizes of ~60 kb and ~35-40 kb (Table 3.4), 
respectively. The GC content of all plasmids was approx. 42%, typical of plasmids associated 
with Enterobacteriaceae. Genetic structure of both plasmids were demonstrated in Figure 3.5 A, 
B. Similar with previous studies, the insertion sequence, ISApl1, was detected upstream of 
mcr-1 in the IncI2 plasmid in PN16 and PN21 (Figure 3.5 C) (Liu et al., 2016). However, no 
insertion sequence was found in front of the mcr-1 gene in the IncX4-type plasmids (Gao et al., 
2016). mcr-1 in PN43 is chromosomally located, and is flanked upstream by ISApl1 and 
adjacent to IS1294 in the downstream (Figure 3.5 C). ISApl1 is always flanked at either or 
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both side of mcr-1, and it has been reported that mcr-1 is frequently transferred with ISApl1 
composite transposon (Poirel, Kieffer, & Nordmann, 2017; Snesrud et al., 2016). IS1294 is an 
IS91-like element, a rolling-cycle transposon (Tavakoli et al., 2000), which suggests that 
IS1294 plays an important role in recombination of mcr-1 segment. 
Table 3.4 Characteristics of mcr-1 positive strains 
No. MLST mcr-1 location 
Plasmid** 
(type/size) 
phylogenetic 
group 
PN16 ST-2040 plasmid 
IncI2 
57,820 bp 
A 
PN21 
Unknown 
(ST-24*) 
plasmid 
IncI2 
~ 60,989 bp 
D 
PN23 ST-1121 plasmid 
IncX4 
~ 33,858bp 
D 
PN24 ST-7986 plasmid 
IncX4 
35,075 bp 
D 
PN25 ST-101 plasmid 
IncX4 
40,590 bp 
D 
PN42 ST-744 plasmid 
IncX4 
39,141 bp 
A 
PN43 ST-410 chromosome NA B2 
*Sequence type for PN21 was determined using E. coli#2 configuration (Jaureguy et al., 
2008) .Other strains were identified following E. coli#1 configuration (Wirth et al., 2006). 
**The plasmid size of PN21 and PN23 were estimated depend on illumina sequencing data. 
Others were on the basis of MinION long reads sequencing data.  
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Figure 3.5 Genetic contexts on plasmids and chromosome in E. coli. A. Genetic structure of 
plasmid from PN16, PN21; B. Genetic structure of PN23, PN24, PN25 and PN42; C. Genetic 
environment of mcr-1 on IncI2, IncX4 plasmids and chromosome. Arrows stand for open 
reading frame (ORFs) and the orientation of transcription. hp: hypothesis protein. 
 
Sequencing analyses comparing the HLCRMs and their respective parental strains, showed no 
mutations in the mcr-1 structural gene resulting in amino acid substitutions for MCR-1 and no 
other non-codon (silent) changes. The immediate genetic context of mcr-1 in each of the 
isogenic sets was also analysed and no mutations in either the promoter or the broader adjacent 
genetic environment could be determined. Interestingly, point mutations were found in PN25 
and PN42 in pmrA and pmrB genes, respectively. The genes pmrB and pmrA encode a 
two-component system (TCS) which is associated with chromosomally encoded colistin 
resistance although colistin resistance in E. coli through pmrB and pmrA changes are 
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considerably less frequent than in Klebsiella and Pseudomonas (S. Sun et al., 2009). In PN25, 
the point mutation in pmrA results in the amino acid substitution R81S. This same substitution 
was previously reported in E. coli and has been inferred as a conserved position in the protein 
resulting in a raised colistin resistance (Alberto Quesada et al., 2014). In PN42, a single 
nucleotide mutation in pmrB resulted in the substitution V161M. Similar substitution (V161G) 
was reported in E. coli previously and gave colistin MIC of 4 mg/L (Alberto Quesada et al., 
2014). Song Sun and colleagues found that the pmrB V161M substitution is associated with 
colistin resistance in S. enterica Serovar Typhimurium and resulted in 32-fold increase in 
colistin MICs (from 0.125 mg/L to 4 mg/L) (S. Sun et al., 2009). However, these changes in E. 
coli are particularly rare (Alberto Quesada et al., 2014). 
Further sequencing analysis on single nucleotide polymorphisms (SNP) between HLCRMs and 
parental strains are ongoing. All SNPs recognised detected so far were listed in appendix. 
Interestingly, in PN25 HLCRM, except for the mutation in pmrA, several point mutations on 
rfaY gene (or waaY) resulted in amino acid substitutions T183Q, T184P, A185L, V186F, 
L187STOP were detected in HLCRM compared to its wild-type parental strain. rfaY gene is 
associated with the completion of the core region of bacterial lipopolysaccharide (LPS) and the 
attachment of O-antigen (Klena, Pradel, & Schnaitman, 1992; Z. Wang, Wang, Ren, Li, & 
Wang, 2015). However, no proof was found that mutation on rfaY gene was related to colistin 
resistance. Thus further experiments such as mutation detection in rfaY and pmrA genes, and 
mcr-1 plasmid knockout are needed to understand the effect of rfaY gene on colistin resistance 
and the main cause of high MIC (128 mg/L) in PN25 HLCRM. 
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3.1.6 Discussion  
In this study, samples from a variety of resources including human and animal and collected 
from Northern Thailand where colistin resistance in E. coli is becoming a national crisis (A. O. 
Olaitan et al., 2016; Srijan et al., 2018). Further analysis of additional isolates from Thailand 
(Uttapoln, personal communication) support my original findings and confirm that that mcr-1 
gene is widely disseminated in animals, humans and the environment in northern Thailand.  
Similarly, to previous studies, many mcr-1 positive strains also harbour other resistance genes 
(Schwarz & Johnson, 2016). For example, all of my isolates except for PN23, contained 
blaCTX-M or/and blaTEM. CTX-M enzymes, which belong to extended-spectrum ß-lactamases 
(ESBLs), contribute to bacterial resistance to third generation cephalosporins, such as 
cefotaxime and ceftazidime (see appendix) – both commonly used to treat severe hospital 
infections throughout Southeast Asia (Lestari, Severin, & Verbrugh, 2012; Suwantarat & 
Carroll, 2016). As colistin is now recognised as a last resort antibiotic for infections caused by 
MDR Gram-negative bacteria, the co-existence of mcr-1 and ESBL genes may reduce 
treatment options for MDR Gram-negative pathogens such as E. coli (Schwarz & Johnson, 
2016). Moreover, we found that mcr-1 positive isolates belonged to the global sequence types 
commonly associated with additional resistance mechanism such as KPC, OXA, NDM and 
rmtC/D (Table 3.4) (Deng et al., 2015; Falgenhauer, Waezsada, Gwozdzinski, et al., 2016; 
Hansen et al., 2016; Kim et al., 2017; Mavroidi et al., 2012; Mushtaq et al., 2011). 
Consequently, pan-drug resistance (PDR) in these MLST groups could potentially rapidly 
develop.  
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According to the S1-PFGE results, the size of mcr-1 plasmids did not show noticeable changes 
(Figure 3.4). Combined with the analysis of WGS results, that no mutations were found in the 
contigs covering the mcr-1 gene, their promoters or adjacent regions between Day0 and 
HLCRMs, these observations may indicate that the mcr-1 gene and its immediate genetic 
context is very stable.  
Although all of the seven isolates were mcr-1 positive, as they were disparate wild-type strains 
with complicated genetic backgrounds, the differences in the generation of HLCRMs is, 
understandably, also likely to be different. In two of the HLCRMs, PN21 and PN25, mutants 
showed a 11- and 3-fold increase in mcr-1 expression. No considerable increase in 
mcr-1expression or mcr-1 copy number was detected in the other HLCRMs. Interestingly, In 
PN25 and PN42, amino acid mutation in PmrA/B was detected in their respective HLCRMs. 
PN25 had R81-S substitution in PmrA, while PN42 had V161M in PmrB, and both mutations 
have been previously reported in E.coli and S. enterica (Alberto Quesada et al., 2014; S. Sun et 
al., 2009). R81 is in the phosphate acceptor domain of PmrA, the mutation leads to a totally 
conserved position of the protein, and V161 is in kinase domain of PmrB. Both substitutions 
may influence the phosphate transfer resulting in colistin resistance in E. coli (S. Sun et al., 
2009). However, for strains PN16, PN23, PN24 as well as PN43, the exact mechanism of 
increase of colistin resistance hasn’t been elucidated. Combined with the results for the stability 
experiment, these data suggest the initiation of mechanisms for temporary acquisition of high 
colistin resistance (except for PN16 and PN24 HLCRMs with low MICs of 16-32 mg/L). 
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3.2 Reduction in bacterial fitness and virulence of HLCRMs 
3.2.1 Growth rate  
After the 14-day passaging, all mutants showed an increase in colistin resistance, some were 
particularly high with colistin MICs up to 256 mg/L. To examine whether this high resistance to 
colistin had an effect on bacterial physiology, a series of growth experiments were undertaken 
on both mutants and the original wild-type strains.   
To examine the growth of the original strains and respective mutants, growth curves of Day0, 
Day3, Day7, Day11 and Day14 for each strain were evaluated in triplicate by testing the OD 
value at 492 nm for 8 hours. For PN16, the Day14 mutant was too weak to recover from -80ºC; 
and therefore, the Day13 HLCRM was chosen as its respective ―end-point‖ mutant. As shown 
in Figure 3.6, all the Day14 mutants (except for PN16) demonstrated a significant lower rate of 
growth compared with their respective wild-type isolates. After 8 hours, the OD value of 
HLCRMs was less than half of wild-type isolates (p < 0.001). 
Although all of the isolates showed an overall gradual decrease in growth rate, the rate varied 
between each HLCRMs (shown in Figure 3.6). For example, PN23 and PN43 HLCRMs 
showed a gradually lower rate of growth over time compared with their parental strains. For 
PN21 and PN25, the growth rate dropped on Day11, while no significant decrease was found in 
bacterial growth of PN16 or its corresponding HLCRMs. PN42 showed an interesting rate in 
growth - on Day3 it dropped; however, on Day7 it recovered and then dropped again on Day11. 
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Figure 3.6 Growth rate collected at OD492nm in 8 hours. A-G. Growth rates for wild-type 
(Day0) isolates as well as Day3, 7, 11, 14 mutants for each strain were examined in 
colistin-free medium for 8 hours. The mean values in triplicate were shown. Error bars 
represented the SD. *PN16 Day14 mutant was unable to grow, so Day13 mutant was used for 
tests. 
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3.2.2 Competition assay 
in vitro fitness cost was further evaluated by competition assay between wild-type strains and 
HLCRMs. E. coli DH5-α labelled by GFP was used as a control. Both wild-type isolates and 
mutants were mixed with GFP-labelled DH5α at approximately 50:50 and were incubated at 
37ºC at 220rpm for 6 hours. The exact ratio at starting and ending points was measured by flow 
cytometry (Figure 3.7, statistical analysis is presented in Table 3.5). Relative fitness was 
calculated by relative ratio between each wild-type strain and HLCRM. Statistical analysis was 
performed using a paired t-test. *= (p < 0.05), **= (p < 0.01), ***= (p < 0.001).  
Except for PN16, all HLCRMs were associated with a significant fitness cost compared with 
their respective wild-type strains. After 6 hours’ incubation, the HLCRMs of PN21, PN23, 
PN24, PN25 and PN42, showed relative fitness of 0.4-0.6 (p =**) to their respective parental 
strain. HLCRM PN43 possessed a relative fitness of 0.78 (p =**) to its respective parent strain, 
yet HLCRM PN16 had a fitness rate similar to its original wild-type strain (with a relative 
fitness of 0.94, p > 0.05). Interestingly, PN21 and PN23 mutants, which showed 11- and 3-fold 
increase in mcr-1 expression level, were associated with the highest fitness cost (relative fitness 
0.41, p =**). 
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Figure 3.7 Relative fitness of each HLCRM and wild-type strain. Relative fitness was 
calculated by relative ratio between each wild-type strain and HLCRM. Means of 6 repeats 
were shown. Error bars represented SD. 
Table 3.5 Statistic analysis of relative fitness 
Relative 
fitness 
repeats mean SD propagated 
errors 
p-value 
PN16-D13 6 0.9380 0.0809 0.0875 0.132 
PN21-D14 6 0.4114 0.0293 0.0816 0.0022** 
PN23-D14 6 0.4083 0.0385 0.1404 0.0022** 
PN24-D14 6 0.4382 0.0133 0.0445 0.0022** 
PN25-D14 6 0.6047 0.0557 0.1196 0.0022** 
PN42-D14 6 0.5169 0.0309 0.0650 0.0022** 
PN43-D14 6 0.7779 0.0534 0.1003 0.0022** 
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3.2.3 Galleria pathogenicity model 
To test the potential decrease of pathogenic potential following generation of HLCRMs, G. 
mellonella were infected with both HLCRMs and their corresponding parental strains. Larvae 
of the wax moth (G. mellonella) are used as a reliable model to measure the pathogenesis of 
several pathogens including E. coli (Jønsson, Struve, Jenssen, & Krogfelt, 2016). Larvae were 
infected with 10
3
 to 10
7
 CFU/ml bacteria and were grown in 37°C for 72h. Death of Galleria 
was checked every 24 hours and survival rates for each strain are shown in Figure 3.9.   
In every case, the wild-type isolates had a higher killing rate than their respective HLCRMs 
(Figure 3.8). Comparing the Galleria killing rate for Day 14 with Day 0; HLCRMs of PN16, 
PN21 and PN23 showed a significantly reduced ability to kill larvae compared to their parent 
strains which is indicative of lower pathogenicity/virulence (pPN16=0.0056**, 
pPN21=0.0029**, pPN23=0.0003***). For strains HLCRM PN42 and PN43, although 
decrease of larvae killing was observed between Day 0 and Day 14, it was not statistically 
significant (p > 0.05).   
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Figure 3.8 Killing of Galleria by HLCRMs and their respective E. coli parental isolates 
expressed as mortality fractions. Mortality of larvae after being injected bacteria for 72 
hours. Ten larvae were tested in each treatment and means of 3 independent repeats were 
shown with SD. Statistical significance was calculated by t-test. *= (p < 0.05), **= (p < 0.01), 
***= (p < 0.001). Concentration of bacteria injected: PN16, PN23, PN24, PN42 and PN43 and 
their corresponding mutants, 10^7 CFU/mL; PN21 and PN25 and their mutants, 10^6 
CFU/mL. 
 
Furthermore, to better understand the trend of decrease in virulence, mutants of Day3, Day7 
and Day11 were also chosen to infect Galleria (Figure 3.9). Generally, the ability of killing 
larvae reduced by time of passage; for example, for HLCRM PN21 the survival rate of Galleria 
increased from 0 to 0.9 by Day0, Day3, Day7, Day11 and Day14. Similar trends were detected 
in strains PN16, PN23, PN24, and PN25. Thus, the HLCRMs show reduced ability to kill larvae 
which is indicative of lower virulence.  
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Figure 3.9 Galleria survival rate for original strain and their respective mutants. A-G. 
demonstrated the percentage of G. mellonella survival (n=30) for 72 hours after being treated 
with wild-type (Day0) strains, as well as Day3, 7, 11 and 14 mutants.   
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3.2.4 TEM on parent and HLCRM E. coli 
Since HLCRM of PN21 showed the highest increase of mcr-1 expression level (-11 fold 
increase), to further understand the effect of mcr-1 expression on LPS and cell outer-membrane, 
transmission electron microscopy (TEM) was undertaken on PN21 and its respective mutant to 
examine the bacterial morphology. However, as shown in Figure 3.10, no significant difference 
was observed at the cell outer-membrane between PN21 and its respective HLCRM. Moreover, 
no obvious cellular degradation of membrane was observed in HLCRMs. Both parental strains 
and HLCRMs possessed an integrated membrane with highly uniform electron density in the 
cytoplasmic region typical of normal cellular structure. 
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A. PN21 
B. PN21-HLCRM 
Figure 3.10 Cell morphology of bacterial outer-membrane for PN21 and its HLCRM.  
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3.2.5 Discussion 
In section 3.1, HLCRMs were acquired after in vitro development at colistin resistance. All of 
the HLCRMs showed higher resistance to colistin than their respective wild-type strains, some 
of which possessed very high levels of resistance to colistin (MIC of 256 mg/L). In this section, 
a series of experiments were undertaken to measure the fitness and virulence of wild-type 
strains (Day 0) and their respective HLCRMs. For growth rates and Galleria models, Day3, 
Day7, Day11 mutants were chosen to examine their trend in fitness and virulence.  
In E. coli, mcr-1 is the main factor that leads to colistin resistance (Shen et al., 2016). According 
to a previous report, the acquisition of mcr-1 plasmids is not associated with a considerable 
fitness cost (Y. Zhang et al., 2017). It can also be hypothesized that the global increase in 
colistin use, as well as the lack of fitness cost for acquisition of mcr-1, may lead to the outbreak 
of high-level colistin resistance in E. coli and the rapid spread throughout the world (Shen et al., 
2016; Zhou et al., 2018). However, due to the fact that mcr-1 always mediates low resistance to 
colistin in E. coli (Liu et al., 2016), studying the effect of high colistin resistant E. coli in 
bacterial fitness is helpful to better understand the relationship of mcr-1 and its host, and to 
predict future trends of mcr-1 mediated resistance in clinical and agricultural sectors.  
There results show that most HLCRMs possess a significant loss in fitness. Compared with 
parental strains, HLCRMs (except for PN16) showed slower growth in colistin free medium. 
Data from competition assays further support that HLCRMs are less competitive than their 
wild-type isolates (relative fitness 0.41-0.78, p=0.002**). The high fitness cost of HLCRMs 
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may limit the spread of E. coli with high colistin resistance in clinical and agricultural 
environments, and could explain the fact that mcr-1 is often associated with a low level of 
resistance to colistin (Liu et al., 2016).  Loss of in vitro fitness cost was observed in the PN16 
mutant – the Day13 mutant was used because of the lack of viability of the Day14 mutant from 
-80°C and had a relatively low resistance (MIC 32mg/L) compared with other HLCRMs.  
The fact that HLCRMs are associated with reduction in fitness has been reported by our recent 
study in Nature Communications, where E. coli Top10, Top10 (pBAD) and Top10 
(mcr-1/pBAD without L-arabinose induction) were passaged with colistin in the same way as 
the 7 wild-type strains in this study (Yang et al., 2017). After 14 days, the colistin MIC of 
TOP10 (mcr-1/pBAD) HLCRMs increased from 0.5 mg/L to 32 mg/L, while TOP10 and 
TOP10 (pBAD) stayed susceptible（with MICs to colistin of 0.5 mg/L). The TOP10 
(mcr-1/pBAD) mutant was correlated with a decrease in fitness compared with E. coli TOP10 
and TOP10 (pBAD) (Yang et al., 2017). These data indicate that HLCRM can be generated 
from laboratory-based isolates after acquisition of mcr-1, and in most cases, this comes with a 
price of lower bacterial fitness (Yang et al., 2017).  
Furthermore, a decrease in virulence by the HLCRMs determined in vivo Galleria models 
further supports this idea. In every case, survival rates of Galleria after being challenged with 
HLCRMs was higher than their respective wild-type parental strains, even for PN16. However, 
the decrease in PN24, PN25, PN42 and PN43 were insignificant (p > 0.05).  Interestingly, 
PN24 and PN25 were assigned phylogenetic group D, PN43 was identified in group B2. E. coli 
strains can be mainly assigned into four phylogenetic groups: A, B1, B2, and D, and virulent 
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strains mainly belong to groups B2 and D, as these groups are normally associated with more 
virulence properties such as biofilm production and hemolysin secretion (Chakraborty et al., 
2015; Soto et al., 2007). The virulent phylotypes may have an influence on the insignificant 
decrease of virulence in PN24, PN25, PN43 HLCRMs as these strains belong to more virulent 
groups. In PN42, the mutant in Day 14 showed higher mortality of larvae compared to Day 3, 7 
and 11 mutants (Figure 3.9 F), which may indicate a ―recovery‖ in virulence in Day14 
HLCRM. However, the mechanism of this increase in virulence remains unclear.  
Colistin resistance by chromosomal mutation is often associated with fitness cost and decrease 
in virulence in species, especially in A. baumannii (Beceiro et al., 2014; Da Silva & Domingues, 
2017). There are two mechanisms leading to colistin resistance in A. baumannii, one is by 
mutations in PmrA/B TCS that modifies LPS resulting in less affinity to colistin and hence 
resistance (Adams et al., 2009), and the other is by mutations in lpx genes resulting in 
completely loss of LPS (Moffatt et al., 2010). Both MCR-1 and mutations in PmrA/B (in A. 
baumannii) lead to resistance to colistin by the addition of phosphoethanolamine (PEA/ pEtN) 
to lipid A (Baron, Hadjadj, Rolain, & Olaitan, 2016; Gao et al., 2016). Induced colistin resistant 
A. baumannii is often associated with a decrease in fitness and virulence (Da Silva & 
Domingues, 2017). López-Rojas et al. measured the fitness and virulence on ATCC19606 and 
colistin resistant mutant RC64. RC64 showed a 32-fold increase to 64 mg/L in MIC compared 
with ATCC19606 (López-Rojas et al., 2011). The resistant mutant showed reduced fitness 
(with competition index of 0.016) and decreased virulence with a higher lethal dose (6.9 log 
colony-forming units vs. 4.9 log units of ATCC19606) (López-Rojas et al., 2011). Beceiro et al. 
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compared the fitness and virulence ATCC19606 and its laboratory-selected mutant (prmB 
mutation). The colistin-resistant mutant showed lower in vitro growth (competition index of 
0.35), and a slight decrease in virulence with a higher reduction in C. elegans brood size 
(Beceiro et al., 2014). However, in the clinical sector, the situation is more complicated since 
resistant bacteria from clinical settings normally have an undefined genetic basis for resistance 
and fitness ( Andersson, 2006; Holmes et al., 2016). Loss of a fitness cost in colistin resistant 
bacteria has been reported (Da Silva & Domingues, 2017). For example, Durante-Mangoni et 
al., collected both colistin susceptible and resistant A. baumannii during a long-term colistin 
therapy from an immunocompromised patient (Durante-Mangoni et al., 2015). The lack of 
fitness cost and decrease in virulence were associated with colistin resistance due to P233S 
mutation in PmrB (Durante-Mangoni et al., 2015). So far, it is unknown whether mcr-1 is 
capable to induce very high colistin resistance in E. coli under clinical or agricultural pressures, 
or its effect on bacterial fitness. However, this study may indicate the possibility of emergence 
of mcr-1-mediated high colistin resistance, and the reversibility as a result of biological cost in 
HLCRMs.  
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Chapter 4: General Discussion 
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4.1 Aims of this study 
Acquisition of antibiotic resistance has been recognised as a relevant problem to human health 
(Hernando-Amado et al., 2017). Bacteria can develop resistance through two different ways: 
vertical evolution by mutations where antibiotic tolerant genotypes are selected and are passed 
to the next generation (Figure 4.1 A); or horizontal evolution where bacteria acquire resistance 
genes via horizontal transfer, including conjugation, transduction and transformation (Figure 
4.1 B) (Sommer et al., 2017). 
Both of these mechanisms are important for the development of antibiotic resistance, especially 
horizontal transfer that contributes to the spread of resistant genes to sensitive organisms 
(Normark & Normark, 2002; Sommer et al., 2017). For example, the ―superbugs‖ mediated by 
blaNDM have been spread to almost everywhere since its first detection in 2008 (C.-R. Lee et al., 
2016). The blaNDM gene is mostly carried by plasmids and can be transmitted among strains, 
species and genus (Khong et al., 2016). The dissemination of these superbugs has prompted 
widespread concern as some organisms are resistant to almost all antibiotics (World Health 
Organization, 2017b).  
Colistin (Polymyxin E) is now listed as a last resort antibiotic to treat serious infections caused 
by MDR Gram-negative bacteria by WHO (World Health Organization, 2017a). Prior to mcr-1, 
resistance to colistin had been reported but was chromosomally mediated, and therefore, in 
terms of dissemination is limited (Liu et al., 2016). The discovery of plasmid-mediated colistin 
resistance via mcr-1, caused worldwide concern as it potentially heralded the end of polymyxin 
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antibiotics (Liu et al., 2016; Walsh & Wu, 2016). Moreover, mcr-1 positive E. coli (MCRPEC) 
isolates were detected in a collection from 1987, which suggests that its appearance is earlier 
than anticipated (Shen et al., 2016). This may explain the reason why MRCPEC had quickly 
been reported all around the world after the first publication of MCRPEC (Schwarz & Johnson, 
2016). 
 
Figure 4.1 Mechanisms of antibiotic resistance acquisition. A. Bacteria gain resistance by 
vertical evolution: mutation(s) within the bacterial genome. Blue cells represent 
antibiotic-sensitive bacteria, and red cells represent resistant organisms; B. Acquisition of 
antibiotic resistance by horizontal evolution:  horizontal gene transfer through conjugation, 
natural transformation and phage transduction (Sommer et al., 2017).   
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It is generally accepted that antibiotic resistance is associated with a cost of fitness to the 
bacterial cell. This cost includes decreased bacterial growth rate, survival rate, transmission of 
resistance rate and disease-causing properties (Sommer et al., 2017). Colistin resistance has 
been reported with a fitness cost in other species such as A. baumannii and K. pneumoniae due 
to chromosomal mutations in PmrA/B or PhoP/Q TCS (Choi & Ko, 2015; López-Rojas et al., 
2011). In A. baumannii, colistin resistance due to mutations in lpxA, lpxC, and lpxD genes leads 
to a complete loss of LPS and is associated with a high fitness cost (Moffatt et al., 2010). 
However, few studies have studied the fitness cost of mcr-1 mediated colistin resistance, 
especially when mcr-1 can only cause comparative low-level colistin resistance (Liu et al., 
2016; Zhang et al., 2017). 
According to previous studies which are somewhat limited, fitness cost studies on acquisition 
of mcr-1 positive plasmids in E. coli, suggest that acquisition of mcr-1 is either associated with 
no reduction or a slight decrease in bacterial fitness (Kong et al., 2017; Liu et al., 2016; Yang et 
al., 2017; Y. Zhang et al., 2017; Zhou et al., 2018). Fitness cost associated with the acquisition 
of antibiotic resistance might reduce the spread of resistance in an antibiotic-free environment 
as it helps sensitive bacteria outcompete resistant organisms (Hernando-Amado et al., 2017). 
No cost resistance may make resistance less reversible (Sommer et al., 2017). Thus the lack of 
fitness cost of acquisition of mcr-1 may aid the maintenance of mcr-1 plasmid under colistin-free 
conditions (Hernando-Amado et al., 2017). 
As mcr-1 expression in E. coli is attenuated to mitigate cellular toxicity, the colistin MICs for 
MCRPEC are invariably 4-16mg/L (Liu et al., 2016). Therefore, the aim of this study was to 
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acquire high-level colistin resistant MCRPEC mutants (termed HLCRMs), and to assess 
whether high-level colistin resistance is associated with a fitness burden and subsequent 
reduction in virulence. To acquire HLCRMs, seven non-clonal wild-type MCRPEC isolates 
were grown under increasing concentrations of colistin for 14 days (Methods and materials 2.4). 
I then examined the fitness and virulence for both wild-type and HLCRMs, including growth 
rate, competition assay and their pathogenic potential in in vivo Galleria models. Additionally, 
the stability of HLCRMs was examined by passaging in the absence of colistin for 14 days and 
reversion frequency calculated. S1-PFGE and WGS analysis were performed to identify DNA 
differences between parental strains and HLCRMs.  
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4.2 Creation and Assessment of HLCRMs 
After being treated with gradually increasing concentrations of colistin, the level of colistin 
resistance for each wild-type MCRPEC strain showed varying degrees (4- to 64-fold increase) 
of increased resistance. E. coli Top10 was used as negative control being treated in an identical 
manner; however, after 14 days, no considerable increase in colistin resistance was observed 
(data not shown). 
In MCRPEC, the level of colistin resistance can be readily increased under the pressure of 
colistin within a short-time frame (14 days). In contrast, when treated in an identical manner, 
mcr-1 negative E. coli invariably maintained their susceptible phenotypes. Unlike K. 
pneumoniae or P. aeruginosa, E. coli rarely are able to mediate resistance to colistin via 
chromosomal mutations – this was the underpinning reason why mcr-1 was first discovered 
(Liu et al., 2016; Urban, Tiruvury, Mariano, Colon-Urban, & Rahal, 2011). Therefore, the fact 
that mcr-1 can enhance E. coli in gaining higher levels of resistance to colistin is perhaps not 
expected. Normally, with MCRPEC isolates, the colistin MICs range from 4-16mg/ml and 
occasionally reaches 32mg/ml (Huang et al., 2017; Liu et al., 2016). However, it is clearly 
possible that with the presence of mcr-1 high-levels of colistin resistance can be obtained.  
In 2/7 HLCRMs,  PN21 and PN25, the mcr-1 expression level was increased 11- and 3- fold, 
respectively, compared with the wild-type parental strains, which may support, in part, that the 
expression of mcr-1 attributes to high-level colistin resistance. However, in the other five 
mutants, the increase in colistin resistance cannot be attributed to mcr-1 expression or the mcr-1 
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copy number (Results 3.1.2). This may indicate that although mcr-1 expression is directly 
associated with E. coli colistin resistance also insusceptibility, other mechanisms must 
contribute to the development of HLCRMs. Interestingly, HLCRMs created from PN25 and 
PN42, showed chromosomal mutations in the PmrA/B TCS. In the case of HLCMR PN25, an 
R81S mutation in PmrA was demonstrated, whilst in the PN42 HLCRM, a V161M mutation in 
PmrB was evident. Both mutations have been previously associated with colistin resistance in E. 
coli (Alberto Quesada et al., 2014); however, the V161M substitution in PmrB from PN42 
HLCRM did not exactly match the variant (V161G) previously reported in E. coli (Alberto 
Quesada et al., 2014). Both substitutions might mediate colistin resistance by affecting 
phosphate transfer between the PmrA/B TCS as R81 is located in the phosphate receiver 
domain of PmrA and V161 is located in the kinase domain of PmrB (S. Sun et al., 2009). 
However, it remains unknown whether these colistin resistance strains in Quesada’s study  
harboured mcr-1, as mcr-1 was reported one year later in 2015 (Quesada et al., 2014, Liu et al., 
2016). Also it is not clear whether the existence of mcr-1 may have an effect on enhancing 
mutations in the PmrA/B TCS under the selective pressure of colistin. It may indicate that the 
presence of mcr-1 affords a degree of protection and cell survival enabling these mutations to 
occur and be selected by the presence of colistin.    
Furthermore, some of the HLCRMs showed the ability of keeping the high-level colistin 
resistance even without presence of the drug. PN25 and PN42 HLCRMs, in which mutations in 
the PmrA/B TCS were identified (HLCRM of PN25 also showed 3- fold increase in mcr-1 
expression), did not demonstrate decrease in bacterial growth or considerable reduction 
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(one-fold decrease) in colistin MICs for 14 days. Therefore, it can be hypothesized that these 
mutations are indeed stable. For HLCRM PN21, no significant decrease in MIC was detected 
even though the growth rate of PN21 reduced by 50% after passaging. In HLCRMs PN16, 
PN23, PN24 and PN43, the exact mechanisms of increasing resistance to colistin were not 
identified, but the result of stability experiments demonstrated that those mechanisms could 
only give a temporary increase in colistin resistance (except for PN24). Further studies are 
needed to understand the mechanisms of these HLCRMs.  
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4.3 How does HLCRMs affect the bacterial fitness and virulence? 
Colistin is a critical important antibiotic, and plasmid-mediated colistin resistance (mcr genes) 
is a cause of great concern to public health (Schwarz & Johnson, 2016). It has been generally 
accepted that acquisition of antibiotic resistance by either target alteration or other mechanisms 
resulting in reduction in bacterial fitness (Melnyk et al., 2015). MCR-1 mediates resistance to 
colistin by modification of the LPS on the bacterial outer-membrane, which is important for 
solute and protein translocation and signal transduction of the cell (Hinchliffe et al., 2017; 
Koebnik, Locher, & Van Gelder, 2000). Some studies recently have shown that acquisition of a 
mcr-1 plasmid has no considerable effect on bacterial fitness, (Kong et al., 2017; Y. Zhang et 
al., 2017) but it remains unknown whether high colistin resistance in E.coli is associated with a 
biological cost.  
In general, the seven HLCRMs showed slower growth (except for PN16) and less competitive 
ability as compared to wild-type parental strains. It can be assumed that under clinical 
conditions or in farm productions, the high resistance will also impose a biological cost (dan i 
Andersson & hughes, 2010; Hernando-Amado et al., 2017). This loss of fitness due to high 
resistance to colistin may explain why mcr-1 is often associated with low MIC values (Liu et al., 
2016). What is more, MCR-1 induced colistin resistance is based on addition of PEA which 
decreases the net negative charge of lipid A and reduces the avidity of colistin binding 
(Hinchliffe et al., 2017). The PEA modification reduces net negative charge of lipid A from -1.5 
to -1, while another cationic substitution by 4-amino-4-deoxy-l-arabinose (L-ara4N) which is 
more efficient decreases negative charge to 0 (Nikaido, 2003). The lower ability of charge 
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alteration by PEA may also have an effect on resistance level to colistin.  
So far, chromosomal mutation based resistance to colistin is mostly dependent on the addition 
of PEA or L-ara4N to the Lipid A moiety of LPS, or rarely by complete loss of LPS (Abiola O 
Olaitan et al., 2014). In many studies, resistant mutants are induced by in vitro treatment with 
sub MIC colistin and meanwhile show decrease in fitness and virulence in A. baumannii and K. 
pneumoniae (Beceiro et al., 2014; Choi & Ko, 2015; Fernández‐Reyes et al., 2009; Mu et al., 
2016). Clinical studies in A. baumannii demonstrate that resistant isolates are often detected 
after treatment with colistin (López-Rojas et al., 2013; Rolain, Roch, Castanier, Papazian, & 
Raoult, 2011). Although reduction of fitness has been identified when compared with 
susceptible isolates and in some instances the lack of biological cost or retention of virulence 
has also been identified (Cannatelli et al., 2014; Durante-Mangoni et al., 2015). In this study, 6 
out of 7 HLCRMs are linked to considerable fitness cost and all mutants displayed a decrease in 
virulence (3 were significant, p < 0.01), which may limit the resistant level in mcr-1 harbouring 
E.coli (Liu et al., 2016).  
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4.4 How might expression of mcr-1effect bacterial fitness and virulence? 
In this study, two of the HLCRMs showed a significant increase in mcr-1 expression. PN21 and 
PN25 showed 11- and 3-fold increase in mcr-1 expression levels, respectively. At the same time, 
the HLCRMs demonstrated a significant biological cost (including decrease in growth rates and 
inferiority in competition assay with the exceptation of PN16 and a decrease in pathogenic 
potential). These data would suggest that high mcr-1 expression levels can lead to lower fitness 
and pathogenicity in E. coli.   
MCR-1 is a member of phosphoethanolamine (PEA) transferase enzyme family and can 
mediate resistance to colistin by modification of LPS on bacterial cell outer-membrane (Liu et 
al., 2016) The MCR-1 enzyme catalyses the addition of PEA to lipid A, which alters the surface 
charge and subsequently leads to a reduction in colistin binding, resulting in colistin 
insusceptibility (Hinchliffe et al., 2017). In our recent report, the increased expression of mcr-1 
not only mediates a significant biological cost (even cell death), but a degradation of the E. coli 
outer-membrane (Yang et al., 2017). LPS, a critical feature of the outer-membrane in 
Gram-negative bacteria, is also likely to be significantly altered (Moffatt et al., 2010). The 
modification of LPS by over-expression of mcr-1 can lead to leakage of the cellular cytoplasm 
resulting in cell death (as shown below in Figure 4.2 [reproduced from Yang et al., 2017]).   
However, in HLCRM PN21, even though it possessed very high level of resistance to colistin 
(MIC of 128 mg/L), no significant modification in the cell wall (thickening of outer-membrane, 
loss of membrane definition and abnormal cytoplasmic morphology) was detected. Compared 
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with the inducible mcr-1 expression model in pBAD vector reported by Yang et al., where the 
over expression of mcr-1 can contribute up to more than 1000- fold increase than un-induced 
pBAD/mcr-1, the mcr-1 expression of PN21 HLCRM showed only an 11- fold increase (Yang 
et al., 2017). As PN21 is a wild-type strain, understanding the mechanism of HLCRM might be 
more complicated. However, it could still suggest that high mcr-1 expression can significantly 
contribute to a reduction in bacterial fitness and virulence. 
 
Figure 4.2 Cellular morphology of inducible mcr-1 in E. coli Top10 by transmission 
electron microscopy (TEM). Over-expression of mcr-1 is induced by 0.2% (w/v) L-arabinose. 
A. B. TEM micrographs of un-induced E.coli; C. TEM micrographs of induced MCRPEC 
(Yang et al., 2017). 
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4.5 Does PmrA/B mutation have an effect on bacterial fitness and virulence 
in mcr-1 harbouring E.coli? 
As the isolates were wild-type strains with various genetic backgrounds, the exact mechanism 
of HLCRM will be challenging to identify. To further understand the mechanism of HLCRMs, 
we compared the genetic context of both HLCRMs and their parental strains. As described 
above, amino acid mutations on PmrA (R81S) and PmrB (V161M) are detected in PN25 and 
PN42 (Figure 4.3), respectively.  
Figure 4.3 Domains of the PmrA/B TCS and positions of mutations conferring colistin 
resistance in this study. PmrA domains, amino acid(aa) positions 1-112: cheY-homologous 
receiver domain(REC); aa 145-216: Transcriptional regulatory protein, C-terminal domain 
(Trans_reg_C). PmrB domains, aa 13-35: First transmembrane domain (TM1); aa 35-66: 
dPeriplasmic domain (PD); aa 66–88: Second transmembrane domain (TM2); aa 89-141: 
Histidine kinases, adenylyl cyclases, methyl-binding proteins, and phosphatases (HAMP 
domain); aa 142–202: Histidine kinase A domain (HisKA); aa 249-356: Histidine kinase-like 
ATPases (HATPase_c). (Abiola O Olaitan et al., 2014) 
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Antibiotic resistance caused by chromosomal mutation is often associated a fitness cost, as 
acquisition of resistance often depends on modification of essential targets such as ribosome, 
DNA gyrase, RNA polymerase or the cell wall (Melnyk et al., 2015; Sommer et al., 2017). The 
alteration of these targets normally has harmful effects on the host and results in reduced fitness 
(Hernando-Amado et al., 2017). Both mutations identified in this study have been reported by 
Quesada et al., whether these mutation mediating colistin resistance are linked to a decrease in 
fitness is not clear (Alberto Quesada et al., 2014).  
In the study by Sun et al., mutations in Salmonella PmrA/B (including R81-H mutation) lacked 
of fitness cost and had a high mutation rate (S. Sun et al., 2009). However, the level of colistin 
resistance was very low (with MICs to colistin < 5mg/L). In other studies, A. baumannii 
(mainly), K. pneumoniae and P. aeruginosa, the reduction in fitness or virulence caused by 
PmrA/B mutation was variable depending on the location, type, and the number of mutations 
(Beceiro et al., 2014; Da Silva & Domingues, 2017). Thus, further studies are needed to 
understand the fitness cost of chromosome-mediated colistin resistance in E. coli.  
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4.6 Limitations and improvements 
According to this study, colistin resistance in isolates harbouring mcr-1 could be enhanced 
under the pressure of increasing colistin concentrations. However, this increase in resistance 
came with a price in fitness as well as virulence. Although it has been shown that high level 
colistin resistance in mcr-1 isolates is associated with a reduction in fitness and virulence; how 
mcr-1 mediates or modulates this process is not clear. Since they are wild-type isolates, the 
genetic basis for their resistance remains uncertain but is part of my future work. As no 
mutation was detected in the mcr-1 structural gene or its surrounding context, and there was no 
obvious increase in mcr-1 copy number, there might exist other mechanisms the bacteria as 
employed to adapt to the pressure of higher concentration of colistin. Further sequencing 
analysing on HLCRMs and parental strains are ongoing and following experiments will be 
undertaken to better understand the mechanism of HLCRMs in this study (eg. Genetic 
expression analysis on efflux pump systems linked to colistin resistance [Warner & Levy, 2010], 
detection of novel mcr genes, and mutation deletion analysis in LPS related genes identified 
in this study.) 
As MCR-1 is a lipid A modifying enzyme, it is not clear that the rate or amount of modified LPS 
is proportional to the level of mcr. With regard to the cell morphology image on PN21 and its 
corresponding HLCRMs (Figure 4.2), the modification on the outer-membrane in the 
HLCRMs could be moderate or even small. Additionally, it is not clear whether the decrease in 
bacterial pathogenicity is associated with the modification of LPS, an important virulence 
factor in Gram-negative bacteria pathogenesis (Kömerik, Wilson, & Poole, 2000; Steimle, 
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Autenrieth, & Frick, 2016). Ergo, further studies are also needed to understand effects of 
modification on LPS or Lipid A and its subsequent effects on bacterial virulence/pathogenicity. 
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4.7 Future work 
The phenomenon of fitness cost associated with AMR is a potential hope to reduce the 
frequency of resistant bacteria, and possibly to reverse antibiotic resistance (dan i Andersson & 
hughes, 2010; Holmes et al., 2016). Experimental studies and theoretical modelling supports 
the reduction of antibiotic use and thereby benefitting fitter susceptible strains over less fit 
resistant strains such that susceptible organisms may outcompete resistant ones in the absence 
of selection (dan i Andersson & hughes, 2010; Hernando-Amado et al., 2017). However, 
several studies have demonstrated that fitness cost can be reduced by compensatory mutations 
and hence help to support the maintenance of antibiotic resistance (Qi, Toll-Riera, Heilbron, 
Preston, & MacLean, 2016). 
In this study, HLCRMs showed a significant biological cost and reduction in virulence 
compared to wild-type parental strains. The results support current surveillance and prevalence 
data that mcr-1 normally only contributes to low-level colistin resistance (Liu et al., 2016). My 
work shows that with a high fitness cost, mcr-1 positive isolates are able to gain very high 
colistin resistance (up to 256 mg/L) within a short time. This significant reduction in fitness 
shows potential reversibility of colistin resistance; however, there is the possibility that after 
compensatory mutations high-level colistin resistant E. coli are stabilized in the population with 
less reversibility of resistance (Qi et al., 2016). 
For future work, it would be interesting to explore fitness adaptations of mcr-1 HLCRMs. As 
shown in stability experiments in this study, some of the mutants showed no decrease in 
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CFU/ml on colistin after passaging for 14 days LB suggesting that HLCRMs can be stable. 
Thus further studies are needed to detect how E. coli would get used or can be attenuated to 
high-levels of colistin pressure, and to predict the reversibility of antibiotic resistance under the 
competition with susceptible phenotypes. Also, further analysing of whole genome sequencing 
in HLCRMs and mutants after stability is needed to better understand the cause of fitness cost 
and potential compensatory evolution. At last, further exploration in SNPs between PN21, 
PN23 and their HLCRMs are needed, especially for PN23, as it contains only one plasmid 
according to S1-PFGE image (Figure 3.4) and result of plasmidFinder (see Appendix).   
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Appendix  
Table 1 Acquired antimicrobial resistance genes 
 PN16 PN21 PN23 PN24 PN25 PN42 PN43 
Aminoglycoside aadA1 aac(3)-IId - aadA1 
aac(3)-IId 
aadA2 
- aph(3')-Ia 
aph(3'')-Ib 
aph(6)-Id 
aadA1 
aac(3)-IId 
aadA5 
aadA2 
aadA2 
aadA1 
aac(3)-IId 
Beta-lactam blaTEM-1B 
blaCMY-2 
blaTEM-1A 
blaCTX-M-55 
- blaTEM-1B 
blaCTX-M-55 
blaCTX-M-14 blaCTX-M-55 
blaCTX-M-14 
blaTEM-1B 
blaTEM-1B 
blaCTX-M-55 
Fluoroquinolone qnrS1 qnrS1 - qnrS1 - qnrS1 qnrS1 
Fosfomycin - fosA4 - - - - - 
MLS - Macrolide, 
Lincosamide and 
Streptogramin B 
mdf(A) mdf(A) mdf(A) 
 
mdf(A) 
mef(B) 
mdf(A) mph(A) 
mdf(A) 
mef(B) 
mdf(A) 
lnu(F) 
Phenicol cmlA1 - - catA2 
cmlA1 
- catA1 
cmlA1 - 
cmlA1 
catA2 
floR 
Sulphonamide sul3 - - sul3 - sul2 
sul3 
sul1 
sul2 
sul3 
Tetracycline tet(M) tet(A) tet(B) tet(A) tet(B) tet(B) tet(A) 
tet(M) 
Trimethoprim - - - dfrA12  dfrA17 
dfrA12 
dfrA12 
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Table 2 Plasmid types in seven wild-type strains  
Strain Plasmid type 
PN16 Col(BS512) 
IncFIA(HI1) 
IncFIB(AP001918) 
IncFIC(FII) 
IncHI1A 
IncHI1B(R27) 
IncI1 
IncI2 
PN21 Col(BS512) 
Col440II 
IncFIA 
IncFIB(AP001918) 
IncFII 
IncI1 
IncI2 
PN23 IncX4 
PN24 IncFII 
IncN 
IncR 
IncX1 
IncX4 
PN25 Col(BS512) 
IncX4 
PN42 IncFII 
IncI1 
IncX1 
IncX4 
PN43 Col(BS512) 
IncFIB(AP001918) 
IncFII 
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Table 3 SNPs identified in HLCRMs assembled to wild-type strains 
Strain Gene Substitution in HLCRMs 
PN16 gspA2 F73Y 
hp V5M, S38P, D42A 
panF several mutations 
garK A9S 
hp C5S, S65R 
hp nucl deletion after K195 
hp D101N 
PN24 hp K229T, R327H 
hp M10L, G14E, M17L, S18G 
uxuA V160E 
hp C187R 
PN25 rfaY L187STOP 
rpoB H551P 
basR (pmrA) R81S 
rhsC V67D 
hp R51K 
PN42 rpob Y1281D 
basS (pmrB) V161M 
aceE1 nuc deletion after M775 
hp G60S, N20D 
hp T13A, L33F 
fadH S97R 
dmlR  I174K 
ywnH Y28C 
rshC 7 A984E 
glmS C134W 
polA K124E 
PN43 aceE  E448STOP 
skp  Q103STOP 
rhsC  
A807S, D814E, F815Y, R845S, 
Q852L, Y853S 
xylE  R540W 
malG  S24W 
 
